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ABSTRACT 
 
 
Radiation therapy has been used as an effective treatment for malignancies in pediatric 
patients. However, in many cases, the side effects of radiation diminish these patients’ 
quality of life. In order to develop strategies to minimize radiogenic complications, one 
must first quantitatively estimate pediatric patients’ relative risk for radiogenic late 
effects, which has not become feasible till recently because of the calculational 
complexity. The goals of this work were to calculate the dose delivered to tissues and 
organs in pediatric patients during contemporary photon and proton radiotherapies; to 
estimate the corresponding risk of radiogenic second cancer and cardiac toxicity based on 
the calculated doses and on dose-risk models from the literature; to test for the statistical 
significance of the difference between predicted risks after photon versus proton 
radiotherapies; and to provide a prototype of an evidence-based approach to selecting 
treatment modalities for pediatric patients, taking second cancer and cardiac toxicity into 
account. The results showed that proton therapy confers a lower predicted risk of 
radiogenic second cancer, and lower risks of radiogenic cardiac toxicities, compared to 
photon therapy. An uncertainty analysis revealed that the qualitative findings of this 
study are insensitive to changes in a wide variety of host and treatment related factors.  
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1. INTRODUCTION AND BACKGROUND 
In this chapter, a brief overview of medulloblastoma (MB) disease is provided 
(Section 1.1), followed by the description of radiogenic late effects for MB patients 
including second cancer (Section 1.2) and cardiac toxicity (Section 1.3). The 
comparative studies between different radiation therapy modalities are discussed 
(Section 1.4). The central problem statement of this work is given (Section 1.5) and 
finally the hypothesis and specific aims are introduced (Section 1.6). 
 
1.1 MEDULLOBLASTOMA 
Medulloblastoma (MB), one of the most common pediatric tumors of the central 
nervous system, accounts for approximately 25% of all pediatric brain tumors. It is a 
malignant tumor that begins in the lower part of the brain (posterior fossa) and can 
spread to the spine or other parts of the body. There are more than 500 cases diagnosed 
annually in the United States (CBTRUS 2002). The median age of the patient at 
presentation is 6-7 years, and the number of male patients is slightly larger than the 
number of female patients (1.2/1). The current standard of care is a combination of 
craniospinal irradiation (CSI) and chemotherapy (Freeman et al 2002). Usually the MB 
patients are categorized into different risk groups: average risk group and high risk 
group. For average risk group, the survival rates are considered satisfactory and the late 
effects are of concern; for high risk group, both late toxicity and poor survival are of 
concern (Fossati et al 2009). 
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The 5-year survival rate of MB patients has improved significantly over the past 
decades (Polednak and Flannery 1995, David et al 1997, Miralbell et al 1997a, 
Miralbell et al 2002, St Clair et al 2004, Fossati et al 2009, Smith et al 2010).  
This increased survival is primarily attributed to the use of postoperative 
radiation therapy (del Charco et al 1998). Radiation therapy typically uses megavoltage 
external beam photon therapy (conventional therapy) to treat the entire craniospinal 
axis.  However, with conventional photon radiation, large amounts of normal tissues 
outside the target receive substantial radiation doses.  These doses are thought to cause 
radiogenic late effects that can diminish the lifespan and quality of life of MB 
survivors. The late effects may occur months, years, or even decades after irradiation 
and may include second cancer, cardiac toxicity, pneumonitis, thyroiditis, cognitive 
deficiency, reduction in fertility and bone growth, etc. (Choux et al 1983, Hoppe-
Hirsch et al 1990, Kiltie et al 1997, Mulhern et al 1998, Fossati et al 2009). 
 
1.2 RADIOGENIC SECOND CANCER 
Cancer is one of the most significant health care problems in the United States. 
It is the leading cause of death for men and women younger than 85. An estimate total 
of 1,529,560 new cancer cases and 569,490 deaths from cancer occurred in the United 
States in 2010 (Jemal et al 2010). Approximately, 1 in 4 deaths is due to cancer in the 
United States, and more than half of the cancer patients will receive some form of 
radiation treatment for their diseases (Dyk 1999). 
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With increasing long term survival rates of the pediatric cancer patients (Hewitt 
2003, Jemal et al 2008), avoiding potentially fatal complications, such as radiogenic 
second cancers, is increasingly important (Newhauser and Durante 2011). Radiogenic 
second cancer is usually fatal and can seriously reduce patients’ quality of life. For 
some types of cancers and in some pediatric cancers, second cancers can cause more 
deaths than the primary cancers (Tubiana 2009). However, the potential incidence of 
second cancer has long been underestimated, and one of the major reasons is the short 
follow-up time and patient survival times were shorter than the latency period for 
second cancer (Tubiana 2009). Second cancers account for 6~10% of all cancers and 
are the fourth or fifth most common cancer in the USA (Neugut 1999). 
Data from the Surveillance, Epidemiology, and End Results (SEER) registries 
demonstrated that childhood cancer survivors are at around 6-fold increased risk of 
second cancers compared to the general population, and the risk continues to increase 
with attained age (Inskip and Curtis 2007). The Childhood Cancer Survivor Study 
(CCSS) (Robison et al 2002), which has the largest cohort of long-term childhood 
cancer survivors,  reported the 30-year cumulative incidence of second malignant 
neoplasms was 9.3%, and that of nonmelanoma skin cancer was 6.9%. Risk of second 
cancers remains elevated for more than 20 years of follow-up for all primary childhood 
cancers (Meadows et al 2009). The overall cumulative mortality for those patients is 
18.1% at 30 years from diagnosis (Armstrong et al 2009). Importantly, the rate of 
mortality attributable to recurrence or progression of primary disease is decreasing, 
while the rate of mortality attributable to second cancers, cardiac death, and pulmonary 
death is increasing (Armstrong et al 2009). 
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There are many risk factors associated with second cancers.  It has been found 
that second cancers are more likely to occur in patients diagnosed with primary cancer 
at a young age, received high-dose radiation therapy and certain chemotherapeutic 
agents, and in those with a known genetic predisposition to cancer (Bhatia and Sklar 
2002). Ionizing radiation is one of the most important treatment-related risk factors.  
The radiation therapy practitioners continually seek out treatment modalities 
that can improve dose conformality to reduce acute toxicity and late effects from 
radiation. One such modality is proton therapy, which delivers a more conformal dose 
distribution and less integral dose to patients than photon therapy (Miralbell et al 
1997b, Lin et al 2000, Miralbell et al 2002, Kirsch and Tarbell 2004, St Clair et al 
2004, Yuh et al 2004, MacDonald et al 2008) because of its physical characteristics. 
Stray dose exists for both photon and proton therapy, but is of greater concern for 
proton therapy because the main component of stray dose from proton therapy is 
secondary neutrons (Agosteo et al 1998, Yan et al 2002, Hall 2006, Zacharatou 
Jarlskog and Paganetti 2008, Fontenot et al 2009, Newhauser et al 2009, Taddei et al 
2009, Taddei et al 2010b).  The main reason for the concern regarding secondary 
neutrons is that the relative biological effectiveness (RBE) for carcinogenesis is not 
well known and some authors have opined that the dose from neutrons may negate the 
advantage of proton therapy (Hall 2006, 2007).While those stray radiation doses are 
typically very low compared to the primary radiation dose, they are not negligible and 
will increase patients’ risks of radiogenic late effects (Suit et al 2007, Tubiana 2009, 
Newhauser and Durante 2011).  
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1.3 RADIOGENIC CARDIAC TOXICITY 
Radiation induced cardiac toxicity, one of the focuses of this work, is of great 
concern because it can be physically and psychologically devastating to patients that 
survive their first cancer. The Life Span Study (LSS) of Japanese atomic bomb 
survivors reported that the mortality from myocardial infarction 40 years after 
irradiation was significantly increased in the survivors who had received the acute dose 
of 1~2 Gy (Preston et al 2003), and there is emerging evidence of risks of 
cardiovascular disease at low radiation dose in those survivors although the dose 
response relation for the risk is not well defined (Little 2009). The CCS found that the 
risk of cardiovascular disease was substantial higher in cancer survivors than the 
general population (Oeffinger et al 2006, Mertens et al 2008, Armstrong et al 2009, 
Lipshultz and Adams 2010), and cardiovascular events are the leading non-malignant 
cause of death among cancer survivors (Mulrooney et al 2009). The American Society 
of Clinical Oncology also reported the estimated aggregate incidence of radiogenic 
cardiac disease for cancer survivors at 10% to 30% by 5 to 10 years after treatment, 
respectively (Carver et al 2007). Radiation therapy was more strongly associated with 
the development of cardiovascular disease risk factors than was chemotherapy 
(Meacham et al 2010), and cardiovascular disease risk increases with time since 
radiation therapy (Mertens et al 2001, Adams et al 2007, Heidenreich et al 2007). 
Coronary vascular disease was found to be associated with higher radiation dose for 
Hodgkin’s disease survivors (Hull et al 2003). Aleman et al (2003) reported that the 
leading noncancer mortality in radiation treated Hodgkin’s disease patients is 
cardiovascular death. Jakacki et al (1993) found that CSI patients are at risk for 
 6 
significant cardiac dysfunction and the asymmetric impairment of heart development, 
where asymmetric distribution of radiation may be the cause. Gurney et al (2003) 
reported that pediatric survivors who received radiation therapy and chemotherapy for 
brain tumors are at increased risk for cardiovascular late effects.  
The major structures of interest in the heart include the pericardium, 
myocardium, valves, conduction system, and coronary arteries (Stewart et al 1995, 
Adams et al 2003). These structures are thought to be at greatest risk radiation induced 
damage.  
Table 1-1 lists the most common radiogenic cardiac diseases and end points, 
biologic models used to analyze dose-response relationship and selected references. In 
order to calculate the risk of cardiac toxicity for various sub-structures of the heart, 
detailed dose distributions of the different heart sub-structures are required because the 
different parts of the heart have different biological functions. 
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Table 1-1 Spectrum of radiogenic cardiovascular disease, end points, biologic models 
used to analyze dose-response relationship and selected references. 
 
Structure End-points Dose-response 
model 
Selected 
references 
    
Whole heart Ischemic heart disease, 
Cardiac mortality 
Lyman model,  
Relative 
seriality model 
 
Gagliardi et al 
1998, 2001, 2010, 
Eriksson et al 
2000, 
Carr et al 2005 
 
Myocardium Restrictive 
cardiomyopathy, 
Angina pectoris,  
Pancarditis, 
Myocardial infarction, 
Myocardial ischemia 
Relative 
seriality model 
Gagliardi et al 
1998, 2001, 2010, 
Adams et al 2003 
 
Pericardium Pericarditis, 
Pericardial effusion, 
Pericardial constriction 
Lyman model, 
Relative 
seriality model 
Martel et al 1998, 
Adams et al 2003, 
Burman et al 
1991, Kallman et 
al 1992 
Valves Valvular stenosis, 
Incompetent valve 
N/A Adams et al 2003 
 
Coronary Arteries Atherosclerosis N/A Adams et al 2003, 
Carr et al 2005 
 
 
1.4 COMPARATIVE STUDIES BETWEEN DIFFERENT TREATMENT 
MODALITIES 
 
Until recently, there was limited knowledge involving accurate organ doses 
associated with stray radiation from advanced-technology radiation therapy. The 
prediction of doses of stray radiation is computationally complex, expensive, and has 
only recently become available for proton therapy (Jiang et al 2005, Koch and 
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Newhauser 2005, Zacharatou Jarlskog and Paganetti 2008, Zhang et al 2008, Fontenot 
et al 2009, Newhauser et al 2009, Taddei et al 2009, Taddei et al 2010b). There is also 
limited knowledge of models to convert dose to risk of radiogenic late effects for 
patients following advanced forms of radiation therapy. Most of the current dose-risk 
coefficients assumed linear-no threshold (LNT) model, which was based on Atomic 
Bomb survivors data and is valid for low dose (0~2.5 Sv). However, at higher dose, the 
cell killing mechanism may suppress the risk from high dose. Different dose-risk 
curves, like linear-exponential model and linear-plateau model, were proposed by 
different studies (Brenner et al 2000, Schneider et al 2005, Sigurdson et al 2005, 
Ronckers et al 2006b, Schneider et al 2008, Fontenot et al 2009). Additionally, 
comparative risk assessments may vary strongly with the treatment site and other 
factors like treatment and host factors, methodology used in the dose reconstruction and 
risk predictions. For these reasons, comparative studies of treatment planning and risks 
of radiogenic late effects are limited in number and scope, and there is a vital need for 
multidisciplinary inquiry into dose reconstruction and risk assessment (Newhauser 
2010).  
St Clair et al (2004) reported a treatment planning comparison between 
conventional  photon, modulated photon and proton therapy for a pediatric patient with 
MB. They found that proton therapy provided substantially superior normal-tissue 
sparing compared to photon therapy and they inferred that the long-term toxicity such 
as cardiac dysfunction could be improved based on the dose sparing. Other similar 
treatment planning studies that compared dose sparing between proton and other 
radiation therapy techniques (Miralbell et al 1997a, Miralbell et al 1997b, Lin et al 
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2000, Tarbell et al 2000, Lee et al 2005, Cochran et al 2008) confirmed that proton 
therapy provides superior sparing of normal tissues than other techniques.  
Miralbell et al (2002) calculated the risk of second cancer after photon and 
proton radiation therapies for a 3-year-old boy with MB, and concluded that proton 
therapy can substantially reduce the second cancer risk. However, that study only 
considered spinal radiation treatment fields and did not include the cranial treatment 
fields.  In addition, the doses reported by Mirabell et al (2002) study were entirely 
based on treatment planning system calculations that did not include stray radiation for 
proton therapy and underestimated stray radiation for photon therapy. Mu et al (2005a) 
investigated different spinal irradiation techniques, and they recommended intensity 
modulated proton therapy (IMPT) for medulloblastoma patients instead of conventional 
photon therapy, IMRT or intensity modulated electron therapy. Again, they did not take 
stray radiation doses into account when they calculated risks. Newhauser et al (2009) 
expanded upon the work from Miralbell et al (2002) by supplementing the therapeutic 
proton therapy doses with stray doses and calculationg the predicted incidence of 
second cancer after CSI. They reported that proton therapies carried a substantially 
lower predicted risk than photon therapies.  However, the predicted risks reported by 
Newhauser et al did not take into account the underestimation of stray dose predicted 
by photon treatment planning systems.   
In all those previous CSI studies, the risk of late effects were either not 
calculated (St Clair et al 2004), or were calculated based on age, sex non-specific risk 
coefficients from ICRP report (Miralbell et al 2002, Mu et al 2005b, Newhauser et al 
2009), which were designed for radiation protection purpose. In addition, these studies 
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had limited consideration of organ doses from stray radiation.  Specifically, for proton 
therapy, stray radiation was either not included (Miralbell et al 2002, Mu et al 2005b) 
or estimated by dose inside a small spherical receptor put in the organs of a 
computational phantom (Newhauser et al 2009). Similarly, for photon therapy stray 
radiation was underestimated because commercial treatment planning systems were 
used to determine organ doses and these systems are known to underestimate stray dose 
(Howell et al 2010). 
Compared to the literature on second cancer following proton radiation therapy, 
reports on other late effects are sparse (Fuss et al 2000, Kaser-Hotz et al 2002, Mu et al 
2005a, Brodin et al 2011). This lack of information is an obstacle to making evidence-
based clinical decisions on choosing a radiotherapy modality.  In recent decades, 
Gagliardi and colleagues (Gagliardi et al 1996, Gagliardi et al 1998, Eriksson et al 
2000, Gagliardi et al 2001, Gagliardi et al 2010) used normal tissue complication 
probability (NTCP) model to calculate radiogenic cardiac toxicity for breast cancer and 
Hodgkin’s disease patients. However, there is still a complete lack of predicted risk 
values for cardiac toxicity following proton or photon CSI. 
 
1.5 STATEMENT OF THE PROBLEM 
 
Radiation therapy has been used as an effective treatment for malignancies in 
pediatric patients. However, in many cases, the side effects of radiation diminish these 
patients’ quality of life. In order to develop strategies to minimize predicted radiation 
complications, one must first be able to accurately estimate pediatric patients’ relative 
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risk for radiogenic late effects, which has not become feasible till recently because of 
the calculational complexity. 
There is still limited knowledge of accurate organ doses and incidence of 
radiogenic late effects. In the case of proton therapy, the dosimetry of whole body 
exposure to neutrons is physically complex and computationally challenging, and 
detailed models that convert dose to effect have only recently become available. 
Although dosimetric data and risk models are available, there is incomplete knowledge 
in the literature of estimated radiogenic secondary cancer and cardiac toxicity for 
pediatric patients who receive advanced forms of radiation therapy. The current gaps in 
knowledge are obstacles to realize an evidence-based approach to clinical decision 
making, i.e., selecting treatment modalities for pediatric patients with the lowest 
achievable predicted risk of late effects. 
The goals of this work are to estimate dose delivered to tissues and organs in 
pediatric patients receiving contemporary proton and photon radiotherapies; to calculate 
the risk of radiation induced second cancer and cardiac toxicity; to test the statistical 
significance of the difference in the predicted risk of radiation induced late effects after 
proton versus photon therapies; and to prototype a tool to enable an evidence-based 
approach for selecting treatment modalities for pediatric patients quantitatively, taking 
second cancer and cardiac toxicity into account. 
 
1.6 HYPOTHESIS AND SPECIFIC AIMS 
 
We proposed to test the following hypothesis: A population of survivors of 
childhood cancer of the central nervous system (CNS) who receive proton CSI are at 
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lower predicted risk of incidence of radiogenic second cancer and cardiac toxicity than 
those who receive photon CSI, and the differences in risk of second cancers and cardiac 
toxicity after photon versus proton CSI are significant. 
To test this hypothesis, we estimated the risk of second cancer for one pediatric 
patient and risk of cardiac toxicity for a population (n=18) of pediatric CNS patients 
undergoing proton therapy versus photon therapies.  To do so, we proformed the 
following specific aims:   
 
Specific Aim 1:  Predict the ratio of relative risk (RRR) and ratio of lifetime attributable 
risk (RLAR) values (defined in section 2.5) of radiogenic second cancer for one 
pediatric CNS patient treated with proton vs. photon therapies according to the 
prevailing standards of care at our institution. 
One pediatric patient was chosen for this aim. A proton plan and a photon plan 
were created using a commercial treatment planning system (TPS). Detailed therapeutic 
dose and stray dose distributions were reconstructed using the TPS, Monte Carlo 
simulations and measurements. Risk models from the literature were used to calculate 
risk of secondary cancer based on therapeutic and stray radiation doses.  
 
Specific Aim 2:  Predict the values of ratio of normal tissue complication probability 
(RNTCP) (defined in section 2.6) of radiogenic cardiac toxicity in a population of 
pediatric CNS patients treated with proton therapy vs. photon therapy using the current 
standards of care. 
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Patients (n=18) of different ages, sexes, sizes, and treatment conditions were 
included in this aim. Photon and proton treatment plans were created for each patient, 
and detailed dose reconstructions were performed for each treatment plan. Normal 
tissue complication probability (NTCP) models from the literature were to estimate the 
risk of developing cardiac toxicity. 
 
Specific Aim 3:  Estimate the uncertainty in the calculated RRR, RLAR and RNTCP 
values (proton vs. photon therapies), taking into account dosimetric uncertainties, 
uncertainties in dose-response model parameters, uncertainty in the mean neutron 
radiation weighting factors and host-specific factors suck as patient sex, size, age at 
exposure and attained age, and treatment related factors.  
We tested for significance by assessing the difference between the median of 
RNTCP values and unity at the 95% significance level. Rigorous error propagation was 
carried out for uncertainties that are comparatively well known, and sensitivity tests 
were carried out for other variables with uncertainties that are less well known. 
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2. METHODS AND MATERIALS 
This chapter describes the methods by which the hypothesis was tested. The 
selection of the population of patients used in this project is described in section 2.1. 
The organs of interest for second cancer and cardiac toxicity risks assessments are 
described in section 2.2. The treatment planning techniques for both proton and 
photon therapies are given in Section 2.3. Section 2.4 describes the method used to 
estimate therapeutic and stray radiation doses for proton and photon treatments. 
Sections 2.5 and 2.6 describe the methods used to calculate risk of second cancers and 
cardiac toxicities. Lastly, the uncertainty analysis is discussed in Section2.7. 
 
2.1 Patient selection  
Patients treated with radiation therapy at The University of Texas MD 
Anderson Cancer Center during 2007 to 2009 were included in this study using the 
consecutive sampling method. Inclusion criteria included: patients of age between 2 
and 18 at the time of treatment, treated with proton therapy in supine position, and 
with CT images available. Exclusion criteria included: Patients treated with photon 
therapy, CT image of patient acquired in prone position, and age younger than 2 or 
older than 18. The reason to choose patients treated with proton therapy is because 
proton therapy treatment plans are much more susceptible to range errors associated 
with CT HU calibration and patient setup errors. Therefore it was much easier to 
recreate photon plans in a proton treatment planning system than to recreate proton 
plans in a photon treatment planning system. Eighteen MB patients were included:  N 
= 10 for patients in group 1, (2 ≤ age ≤ 10), N = 8 for patients in group 2, (10 < age ≤ 
18). The patients in our sample include patients with different ages, sexes, sizes, 
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statures and treatment techniques that are representative of the MB pediatric 
population at our institution. 
 
2.2 Organs at risk 
The organs of interest for second cancer study in specific aim 1 included 
stomach, colon, lungs, bladder, thyroid, liver, gonads and remainder (i.e., all other 
tissues/organs for which organ-specific risk coefficients were not explicitly provided 
in the BEIR VII report). Skin and bone marrow were not included in this study for 
simplicity. These organs were delineated on the planning CT images of each patient.  
For the cardiac toxicity study in specific aim 2, the major structures of interest 
in the heart included the pericardium, myocardium, valves, conduction system, and 
coronary arteries (Stewart et al 1995, Adams et al 2003). These structures were 
thought to be at greatest risk for damage induced by irradiation. Table 1-1 lists the 
structures, end points, dose-response models, and selected references. Because the 
different parts of the heart have different biological functions, in order to calculate the 
risk of cardiac toxicity for various sub-structures of the heart, the detailed dose 
distributions throughout the entire organ were reconstructed. 
The heart was contoured in detail because of the complexity and different 
radiation sensitivities of the heart sub-structures: the external surface of the heart was 
contoured in every CT slice, from the inferior border of the right pulmonary artery to 
the apex of the heart; the pericardium was defined as a 2-mm shell inside the external 
heart surface contours; the myocardium had an external contour identical to the 
internal contour of pericardium, and thickness of the myocardium varied from 1 cm to 
2 cm, with the wall thickness of the left part being twice that of the right part.  
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2.3 Treatment planning 
Both proton and photon treatment plans were created using a commercial TPS 
(Eclipse version 8.9, Varian Medical Systems, Palo Alto, CA). For all the patients, 
multiple radiation therapy fields were designed to treat the entire craniospinal axis. 
The final plans for each patient were approved by a board certified radiation 
oncologist.  More details about the proton and photon radiotherapy treatment plans 
can be found in sections 2.3.1-2 below and in Howell et al (2011). 
2.3.1 Proton treatment plans 
 
The proton treatment plans were designed to treat the patient using the 
passively scattered proton beam line at our institution (Arjomandy et al 2009). The 
treatment planning system was previously configured and tested for clinical use 
(Newhauser et al 2007b). The patients were treated in the supine position and the CT 
scans were obtained from the top of the head to the thigh or lower. An age-specific 
target volume was defined for each patient. For patients < 15 years of age, the target 
volume included the brain, spinal canal, and the entire vertebral body (to prevent bone 
growth deformity due to non-uniform dose distribution in the vertebral body).  For 
patients ≥15 years of age, the target volume included the only the brain and spinal 
canal (with 2-3 mm margin anteriorly). The proton treatment plan was designed to 
deliver CSI of 23.4 Gy (RBE) to the target volume (including brain and spinal canal) 
(i.e., 21.3 Gy × 1.1 RBE) with 1.8 Gy (RBE)/fraction.  The boost fields were not 
considered in this study for simplicity, and because the contributions of boost fields to 
stray doses were previously found to be negligible (Taddei et al 2009). The proton 
treatment plans included right and left posterior oblique cranial fields (gantry angle of 
255o and 105o) and one to three posterior-anterior spinal fields (gantry angle of 180o) 
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depending on the length of the spine. Patient-specific devices included a range 
compensator and field-defining collimator. The standard of care for proton treatments 
at our institution included one to three junction shifts, which were generally one to 
two cm apart, to reduce the hot and cold spots at the field junctions. In this project, 
however, the junction shifts were eliminated because the hot and cold spots were 
dosimetrically irrelevant to second cancer and cardiactoxicity risks. Also, the 
treatment plans were used as the basis for stray radiation dose calculations and it was 
not feasible to repeat these stray dose calculations multiple times because of junction 
shifts.  The treatment plans were initially calculated with junction shifts and then we 
removed the junction shifts and reoptimized the plans to achieve approximately the 
same uniformity as the plans with shifts (Giebeler, personal communication).   
2.3.2 Photon treatment plans 
The photon treatment plans typical contained the following fields: two 
opposed lateral cranial fields (gantry angles of 270o and 90o), and one or two 
posterior-anterior spinal fields (gantry angle of 180o) depending on the length of the 
spine. All photon fields were 6 MV. The plans were designed to deliver 23.4 Gy to the 
cerebrospinal fluid volume (including brain and spinal canal) with 1.8 Gy/fraction. 
The plans included junction shifts after 9 Gy and 16.2 Gy. At our institution, an 
intensity modulated field-in-field (FIF) technique was used to reduce dose 
heterogeneity in the field matching areas (Yom et al 2007): the FIF technique uses 
multiple lower-weighted reduction fields, which contain blocked segments 
strategically placed within primary cranial spinal fields to reduce the highest dose 
areas and to force greater homogeneity in the target volume (Howell et al 2011).  
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2.3.3 Evaluation volume 
 Evaluation volumes were created to provide to compare dose distributions 
from proton and photon treatment plans.  The evaluation volume included the entire 
CSF volume (including the brain and spinal canal through S2).  This was done 
because the proton plans used an age specific 3-dimensional target volume and the 
photon plans did not have an explicit 3-dimensional target volume (they were simply 
designed to cover the CSF volume).  
  
2.4 Therapeutic and stray radiation dose reconstructions 
The therapeutic doses in proton and photon therapies were taken from the 
dose-volume histograms (DVH) calculated by the TPS. Organs whose risk 
coefficients were not explicitly provided in the BEIR VII report were included in 
“remainder”, and the dose to it was estimated as the mean dose for all the other organs 
(excluding skin and bone marrow).  
Because the TPS did not calculate stray radiation doses accurately for photon 
and proton therapies, we used supplemental methods. Sections 2.4.1 and 2.4.2 
describe the techniques used to determine the stray radiation doses during proton and 
photon therapies, respectively. 
2.4.1 Stray dose reconstructions for proton therapy 
Previous publications indicated that the patient can be exposed to whole body 
neutron dose about several hundred mSv during proton CSI proton (Newhauser et al 
2009, Taddei et al 2009). Each patient requires a unique treatment technique and the 
impact of inter-patient variations in treatment technique is not known. Therefore the 
stray neutron doses were reconstructed for each patient included in this study. 
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The stray dose associated with the proton treatment was estimated by Monte 
Carlo transport calculations using the Monte Carlo N-Particle (MCNPX) code 
(version 2.6, Los Alamos National Laboratory) (Hendricks et al 2006). Its suitability 
for simulating radiation dose has been well established (Fontenot et al 2005, Herault 
et al 2005, Koch and Newhauser 2005, Newhauser et al 2005, Polf and Newhauser 
2005, Polf et al 2005, Tayama et al 2006, Fontenot et al 2007, Herault et al 2007, 
Newhauser et al 2007a, Newhauser et al 2007c, Zheng et al 2007, Koch et al 2008, 
Moyers et al 2008, Titt et al 2008, Zheng et al 2008, Bednarz et al 2009, Fontenot et 
al 2009, Newhauser et al 2009, Athar et al 2010, Bednarz et al 2010, Taddei et al 
2010a, Taddei et al 2010b, Zhang et al 2010, Mowlavi et al 2011). The treatment plan 
for each patient was imported into an in-house Monte Carlo Proton Radiotherapy 
Treatment Planning (MCPRTP) code system (Newhauser et al 2007b, Newhauser et 
al 2008) and the code system models the proton beam delivery system (Newhauser et 
al 2007b) and the patient (Figure 2-1). The voxelized patient phantom was created 
based on the CT images of the patient as described in Newhauser et al (2007a) and 
Taddei et al (2009). The three-dimensional CT image matrix was segmented into 4×
4×5 mm3 voxels because of a memory constraint in the Monte Carlo system. The 
matrix of Hounsfield Unit values in these voxels was then converted into a 
corresponding matrix of material composition indices and a matrix of mass density 
values. The elemental material compositions of tissues were taken from Woodard and 
White (1986). The material list was read as a text file by the MCNPX input file using 
the READ card in MCNPX. 
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Figure 2-1. Proton therapy treatment apparatus and the voxelized phantom oriented 
for the superior spinal proton field. The beam delivery system includes a vacuum 
window (A), a beam profile monitor (B), a range modulator wheel (C), a second 
scatter (D), a range shifter assembly (E), backup and primary monitors (F), the snout 
(G), the range compensator (I), treatment couch (I) and the patient (J). 
 
 
Stray neutrons were generated both in the treatment unit (external neutrons) 
and in the patient (internal neutrons). Separate simulations were performed to predict 
the dose from external and internal neutrons, and total neutron dose was the 
summation of them. Details of the simulation methods were described previously 
(Newhauser et al 2009, Taddei et al 2009).  
For each patient, we tracked 5×108 source particles for each cranial field stray 
neutron dose simulation and 1×109 source particles for each spinal field stray neutron 
dose simulation. As mentioned above, the external and internal neutron simulations 
were separated. Statistical uncertainties in doses were reported at the 68% confidence 
interval by MCNPX. The simulations were run in parallel on a 1072-CPU cluster with 
2.6-GHz, 64-bit  processors and the average total computation time for one patient 
simulation was approximately 4×104 cpu·hours.  
The equivalent dose in each organ, HT, was calculated by multiplying the 
organ dose by the mean radiation weight factor, Rw . The Rw  values were taken as 1.1 
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for therapeutic proton and 1 for photon beams, respectively. For stray neutrons, Rw  
values were taken from a study by Newhauser et al (2009), in which the mean neutron 
radiation weighting factors were estimated based on organ-specific simulations of 
neutron spectral fluence. They simulated neutron spectral fluence within the organs of 
an anthropomorphic computational phantom receiving CSI, and they calculated Rw  
values based on ICRP Publication 92 recommendations (ICRP 2003). The mean Rw  
values averaged over all organs were 7.75 for the cranial fields, 8.09 for the superior 
spinal field and 8.17 for the inferior spinal field. These values were applied to the 
corresponding fields in this study, and the average Rw  values (8.13) between superior 
and inferior spinal field was used for middle spinal field in this study. 
 
2.4.2 Stray dose reconstructions for photon therapy 
Stray dose in photon therapy was obtained from the TPS or thermoluminescent 
dosimeter (TLD) measurements in a realistic anthropomorphic phantom. 
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Figure 2-2 The commercial anthropomorphic phantom used for stray photon dose 
measurement 
 
 
Howell et al (2010a, 2010b) recently reported a methodology for determining 
radiation doses for organs either in-field, out-of-field or partially in-field: for in-field 
organs (the entire organs were within the 5% isodose line), the organ doses were 
obtained from TPS directly; for out-of-field organs (no part of the organ received 
more than 5% of the prescribed dose), the mean doses from TLD measurements in 
phantom were used; for partially in-field organs, a combination of TPS dose result 
and TLD measurement was used. 
An anthropomorphic phantom (ATOM, CIRS, Inc., Norfolk, VA) was used for 
stray dose measurement (Figure 2.2). The measurement was performed by Howell et 
al (personal communication).  The phantom was transected longitudinally in 2.5 cm 
slices and included a grid of holes that held TLD capsules.  A CT scan of the phantom 
was acquired and then imported into the TPS.  A 6 MV FIF photon treatment plan was 
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developed to irradiate the entire cranial and spinal region of the phantom; the 
treatment plan was consistent with the planning methodology used for the patient 
treatment plans (described in section 2.3). Measurement locations were defined 
throughout the phantom at various distances from the field edge.  Further details of 
photon stray dose measurement were reported by Howell et al (2011).  
For the cardiac toxicity study, all heart sub-structures in all patients were 
within the 5% isodose surface (Figure 2-3).  Recent work by Howell et al found that 
doses reported by the TPS used in this work were accurate to the level of the 5% of 
the prescribed dose.  Therefore, the dose reported by the TPS for the heart (and 
substructures of the heart) was used for risk calculations. The photon stray dose to 
thyroid was also obtained from TPS directly because the thyroid was included in the 
5% isodose surface for all patients considered. 
 
5%
100%
 
Figure 2-3 Sagital slice of absorbed dose distribution for the photon plan for a 4-year-
old boy. The heart was included in the 5% isodose surface (yellow). 
 
 
For organs other than the heart and thyroid, they were first categorized as in-
field, out-of-field, or partially in-field organs, and then the methodology of Howell et 
al (2010) was used to calculate organ doses.  
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2.5 Calculation of risk of second cancer 
As stated in specific aim 1, the ratio of relative risk (RRR) value of radiogenic 
second cancer was calculated for one pediatric CNS patient treated with proton vs. 
photon therapies. A 4-year-old boy diagnosed with medulloblastoma was chosen for 
this purpose to facilitate comparison with previous studies from Miralbell et al (2002) 
and Newhauser et al (2009). The proton treatment technique for this patient is listed in 
Table 2-1. 
Table 2-1 Proton beam specifications of the CSI fields. 
 
 A B C D 
Target Cranium Cranium Upper  
spine 
Lower 
spine 
Proton energy at nozzle entrance (MeV) 180 180 160 160 
Range in patient (cm H2O) 16 15.7 10.9 10.7 
SOBP width (cm H2O) 16 16 5 6 
Gantry angle (degree) 255 105 180 180 
Air gap (cm) 10.8 11.3 115 11.8 
Aperture thickness (cm) 6 6 4 4 
Prox margin around CTV (cm) 0.3 0.3 0.3 0.4 
Distal margin around CTV  (cm) 0.8 0.8 -0.2 0 
 
The models contained in the report of the committee on the Biological Effects 
of Ionizing Radiation (BEIR VII) (NRC 2006) was used to calculate risk of radiogenic 
second cancer based on radiation doses determined in section 2.4 of this work. 
The risk of developing a radiogenic cancer depends on many host and 
treatment factors, including the amount of radiation, age at exposure, attained age, and 
sex. Allowing for adjustments of the models based on these factors, the BEIR-VII 
committee provided organ-specific linear-no-threshold (LNT) risk models suitable for 
the estimation of excess relative risk (ERR) at low-dose and low-dose rate exposures. 
For each organ or tissue, T, ERRT was defined as:  
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ERRT = RRT – 1,                                                         (2-1) 
where RRT is relative risk for the organ or tissue T and was defined as the ratio of 
disease incidence rates in exposed and unexposed groups.  
The BEIR-VII committee recommended the following equation to calculate 
ERRT: 
η
γβ 




=
60
)exp( * aeHERR TsT ,                                    (2-2) 
where HT is the equivalent dose in Sv and is the sum of doses from multiple 
therapeutic fields and stray radiation doses generated from each therapeutic field to a 
certain organ, e is age at exposure in years, e* is (e – 30) /10 for e < 30 and zero for e 
> 30, and a is attained age in years, sβ is the sex-specific, organ-specific instantaneous 
ERR/Sv value, γ is the per-decade increase in age at exposure over the range 0–30 
years, and η is the exponent of attained age (η = 0 for thyroid because the model for 
thyroid in the BEIR VII report is not dependent on attained age). Values for sβ , γ, and 
η were taken from Table 12-2 of BEIR VII.  Using these data and equation (2-2), we 
estimated risk of second cancer at various times since exposure, e.g., at 15, 30, 45, 60, 
75 and 95 years after radiotherapy. Equation (2-2) was based on the LNT model. 
However, other effects may come into play at high radiation dose such as cell 
sterilization effect. These will be discussed in the uncertainty analysis section 2.7. 
The BEIR VII report defined Excess Absolute Risk (EAR) as the difference 
between the cancer incidence rates of the exposed and unexposed groups. BEIR VII 
report also defined Lifetime Attributable Risk (LAR) as the probability that an 
irradiated patient will develop a radiation-induced second cancer during his or her 
lifetime (living to 100 years) exposed to certain equivalent dose HT at age e, and it 
recommended that LAR should be estimated using both relative and absolute risk 
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transport models. The LAR coefficients of cancer incidence were provided in Table 
12D-1 in the BEIR VII report, which were used to calculate cumulative lifetime risk 
of second cancer incidence. For simplicity, EAR coefficients were used to calculate 
the cumulative risk of radiogenic second cancer incidence of this patient living to 
certain years and was exposed at 4 years (age at exposure for this patient).  
For each modality, the total LAR was calculated as  
alityT
Tality LARLAR
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mod 





= ∑   ,                                   (2-3) 
where the sum is over all the organs or tissues. And to compare the risks between 
proton and photon therapies, the ratio of lifetime attributable risk (RLAR) was 
defined as 
RLAR = LARproton / LARphoton                                    (2-4) 
 
 
2.6 Calculation of risk of cardiac toxicity 
There is growing interest in developing models that predict the risks of late 
effects based on the radiation dose (Gagliardi et al 1998, Eriksson et al 2000, 
Gagliardi et al 2001, Merchant et al 2002, Blanco et al 2005, Chapet et al 2005, 
Krasin et al 2005, Yorke et al 2005, Merchant et al 2006, Kong et al 2007, Merchant 
et al 2008). However, as yet, such late-effect calculations have not been performed 
routinely in the radiation treatment planning process for a variety of reasons: normal 
tissue complication rates among patients were low   (Moiseenko et al 2000, 
Schultheiss 2001, Yorke 2001); patient survival times for patients with some first 
cancers were historically shorter than the latency period for late cardiac toxicity; the 
importance to minimize radiation late effects was not as fully appreciated; and 
adequately detailed dose response models were not available; until recently, the 
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computation of accurate doses to organs and tissues of the whole-body was not 
feasible for advanced-technology radiotherapies. 
Based on a comprehensive literature search (listed in Table 1-1), the relative 
seriality (RS) model (Kallman et al 1992) and Lyman model (Lyman 1985) were used 
to calculate the Normal Tissue Complication Probability (NTCP) of radiogenic 
cardiac toxicity. These methods are briefly reviewed for the convenience of the 
reader. 
The RS model is based on the Poisson model of cell survival. The probability 
of cell death when irradiating a tissue to a dose D is 
50exp{ (1 / )}( ) 2 e D DP D γ− −= ,                                                (2-5)
 
where γ is the maximum relative slope of the dose-response curve, D
50
 is the dose that 
will result in 50% complication probability. The cumulative complication probability 
due to an inhomogeneous irradiation is given by 
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where s is the relative seriality which describes the hybrid serial/parallel architecture 
of the organ, (s = 0 indicates parallel organization while s = 1 indicates serial 
organization), n is the number of sub-volumes in the dose-calculation volume, Di is 
the dose in each sub-volume and Vi is the volume of each sub-volume in the 
differential DVH, and V
 
is the total volume of the organ.  
The Lyman model assumes is that the probability of complication is a normal 
distribution as the function of dose for the uniformly partial radiated volume V. The 
cumulative complication probability is given by 
                   
2 /21 d
2
t tNTCP e t
π
−
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= ∫                                            (2-7) 
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t = (D – TD50(V))/(m·TD50(V))                                    (2-8) 
TD50(V) = TD50(1)/Vn                                             (2-9) 
where TD50(V) is the tolerance dose that would result in 50% complication probability 
for the partial volume V, and TD50(1) is the tolerance dose that would result in 50% 
complication probability for the full organ, n indicates the volume effect (n close to 1 
means there exists strong volume effect) , and m is inversely proportional to the slope 
of dose-response curve. 
 The NTCP models give a quantitative prediction of organ response to radiation 
based on a dose distribution. They calculate the cumulative risk of normal tissue 
complications. The NTCP models used in this work were not age or sex specific, 
which is a limitation that will be discussed in section 4.7. 
 To compare NTCP values between photon and proton plans, the ratio of NTCP 
values (RNTCP) was defined as 
proton photon/RNTCP NTCP NTCP= .                                        (2-10) 
For each patient DVHs for heart sub-structures were exported from TPS to 
calculate the corresponding NTCP values. Each step in the differential DVHs was 
corrected to 2 Gy(RBE)/fraction schedule by using the linear quadratic model (Steel 
2002). The α/β ratio of 3 was chosen for the late effects in the heart (Eriksson et al 
2000). 
Table 2-2 lists NTCP model parameter sets used to model cardiac toxicity from 
the literature. These studies include models for patients treated for Hodgkin’s disease 
(Eriksson et al 2000), breast cancer (Gagliardi et al 1996, Eriksson et al 2000, 
Gagliardi et al 2001), esophageal cancer (Martel et al 1998) and historical data which 
were mostly based on patients with Hodgkin’s disease and breast cancer (Burman et 
al 1991, Kallman et al 1992). The literature contained no reports containing detailed 
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dosimetry and clinical outcomes data on cardiac toxicity for CSI patients. 
Consequently, NTCP model parameters specifically for CSI patients are not available. 
The model parameters listed in Table 2-2 were initially used for cardiac toxicity 
calculations for one pediatric patient. Based on calculation results for this first patient, 
shown in Table 3-11 in section 3.3, the following NTCP parameters were used for the 
baseline cardiac toxicity calculations for the entire sample: pericardium: D50 = 50.6 
Gy, n = 0.64, m = 0.13; myocardium, D50 = 52.2 Gy, γ = 1.25, s = 0.87; for whole 
heart the average of three sets of parameters in Table 2-2 were used: D50 = 62 Gy, γ = 
1.06, s = 1. Sensitivity tests were performed to quantify the impact of using different 
sets of NTCP model parameters for cardiac toxicity predictions. 
Table 2-2 NTCP model parameters for cardiac toxicity from the literature. 
  Pericardium Myocardium Whole heart 
Eriksson 
et al (2000), 
Hodgkin’s 
disease 
  
 
 
 
Parameters 
Burman et 
al (1991), 
Hodgkin’s 
disease + 
breast 
cancer 
Martel 
et al 
(1998), 
esophagus 
patients 
Kallman 
et al 
(1992), 
Hodgkin’s 
disease + 
breast 
cancer 
Gagliardi 
et al (2001), 
breast 
cancer 
Gagliardi 
et al 
(2001), 
breast 
cancer 
Eriksson 
et al 
(2000), 
Hodgkin’s 
disease + 
breast 
cancer 
 
Lyman 
Model 
D50 48 50.6 - - - - - 
 n 0.35 0.636 - - - - - 
 m 0.1 0.13 - - - - - 
RS 
Model 
D50 - - 49.2 52.2 52.3 63.3 70.3 
 γ - - 3 1.25 1.28 0.93 0.96 
 s - - 0.2 0.87 1 1 1 
 
 
2.7 Uncertainty analysis  
 
The baseline calculations of second cancer risk were based on the LNT model, 
which is mostly based on low dose data (<2.5 Sv) from atomic bomb survivors (NRC 
2006). However, at higher doses, the cell sterilization mechanism may be important 
(Sigurdson et al 2005, Ronckers et al 2006a, Bhatti et al 2010) and other possible 
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non-linear dose-response relationships, e.g. linear-plateau relation and linear-
exponential relationship may be more accurate (Hall and Wuu 2003, Schneider and 
Kaser-Hotz 2005). Fontenot et al (2010) recently estimated the uncertainties in risk 
calculations following photon and proton radiotherapies for prostate cancer based on 
rigorous error propagation (eq. 2-9, based on Fontenot et al (2010) and was modified 
for Ratio of Lifetime Attributable Risk (RLAR) analysis. RLAR = LARproton / LARphoton) 
and sensitivity tests. They concluded the baseline calculations of risks showed only a 
small sensitivity to cell sterilization effects. The relative uncertainty in RLAR is given 
by 
1 2 1 2
2 2 2 2
2 2 2 2
1 2 1 21 2 1 22
2 2
T T T TD D D D
T TT T T TRLAR
T T
T T
h p
LAR LAR LAR LAR
D D D D
RLAR
LAR LAR
σ σ σ σ
σ
          
   + +                          = +    
        
               
∑ ∑
∑ ∑
       (2-9) 
where 
1
1
TD
TD
σ 
  
 
is the relative uncertainty in the therapeutic dose, and 
2
2
TD
TD
σ 
  
 
 is the 
relative uncertainty in the stray dose. The subscript h denotes proton therapy, and 
subscript p denotes photon therapy. A similar uncertainty analysis was also applied to 
the calculated risk second cancer in thyroid for one patient in this study, because the 
dose-risk relationship for thyroid is apparently not linear (Sigurdson et al 2005, 
Ronckers et al 2006a, Bhatti et al 2010) 
As discussed in section 2.6, NTCP model parameters specifically for cardiac 
toxicity for CSI pediatric patients were not available. Considering the potentially large 
unknown uncertainties in the NTCP model parameters, we used different set of 
parameters to calculate NTCP for each heart sub-structure for one patient. More 
specifically, each NTCP parameter was varied over its plausible range (for Lyman 
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model, 10 ≤ D50 ≤ 100 Gy, 0.1 ≤ n ≤ 1, 0.1 ≤ m ≤ 1; for RS model, 10 ≤ D50 ≤ 100 Gy, 
0.1 ≤ γ ≤ 3, 0.1 ≤ s ≤ 1) to test the sensitivity of RNTCP to changes in each parameter. 
In the sensitivity test, the intervals of NTCP parameters were chosen to include any 
parameter values in the literature, so they covered the baseline parameters and the 
calculation results based on those parameters bounded the real cardiac toxicity risk 
calculation for CSI patients. 
There are large uncertainties in the value of the mean radiation weighting 
factor values for neutrons. The ICRP Publication 92 (2003) recommended a 
maximum neutron radiation weighting factor of 20. A recent reanalysis of atomic 
bomb survivors data deduced that the 95% confidence interval of neutron RBE was 
25~400 (Kellerer et al 2006). Newhauser et al (2009) pointed out that patient’s 
second cancer risk from passively scattered proton therapy will be lower than 
conformal photon therapy for CSI even if the neutron Rw  values were increased by a 
factor of 35. Fontenot et al (2010) also concluded that proton therapy conferred lower 
predicted risks than photon therapy for prostate cancer as long as neutron Rw  values 
were less than 100 (scaled by a factor of 5).  In this study, the sensitivity test 
quantified the impact of uncertainty in the Rw  values by using different scaling 
factors in both second cancer and cardiac toxicity calculations. 
Contouring of heart sub-structures is challenging and may introduce large 
uncertainties. Imaging methods for the current standards of care for external beam 
radiation therapy at our institution did not clearly show those sub-structures, and it is 
hard to differentiate the heart border from the liver and diaphragm. The heart also 
moves with respiratory and cardiac cycles. The definition of the heart sub-structure is 
not standardized and the dosimetric impact of the uncertainty in heart contours is not 
well understood. For those reasons, we varied the thickness of different heart-
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substructures to see how sensitive the baseline risk predictions would be to the 
uncertainties in heart contouring. 
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3. RESULTS 
This chapter describes the results of dose reconstruction for both proton and 
photon therapies (section 3.1), followed by calculations of risks of second cancer 
(section 3.2) and cardiac toxicities (section 3.3). The sensitivities of the baseline risk 
calculations to changes in the key variables were analyzed for second cancer in section 
3.4 and cardiac toxicity in section 3.5.  
 
3.1 Therapeutic and stray radiation doses reconstructions 
The tables and figures below summarize the therapeutic absorbed dose and stray 
radiation dose to heart sub-structures from photon and proton CSI. 
3.1.1 Evaluation volume coverage for photon versus proton treatment plans 
Photon and proton CSI both provided equivalent coverage of the crainospinal 
axis.  This was evaluated by comparing the population-averaged percent volume 
receiving the prescription dose of 23.4 Gy (RBE) (V23.4) for the evaluation volumes for 
photon and proton CSI.  A paired t-test indicated no significant difference in the V100 
for the two modalities.  The maximum dose (Dmax) in the evaluation volume was 
greater for photon than for proton therapy (p < 0.01).  These results are summarized in 
Table 3-1 (Howell et al 2011). 
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Table 3-1 Comparison of target coverage and the maximum dose in the target between 
photon and proton CSI (Howell, personal communication).  
 
 
Photons 
(Gy(RBE)) 
Protons 
(Gy(RBE)) 
Parameter Mean SD Mean SD 
t-test                
p-value  
Level of 
significance  
V23.4 99.36 1.04 99.23 0.88 6.96E-01 NS* 
Dmax 28.13 15.21 26.05 7.87 1.60 E-05 <0.01 
* Not significant. 
3.1.2 Dose reconstruction for photon therapy 
 
Figure 3-1 shows the absorbed dose distribution in a representative pediatric 
patient (patient no. 2, a 4-year-old boy) from therapeutic photon treatment fields. The 
treatment plan provided adequate coverage of the target: cerebrospinal fluid volume 
(including brain and spinal canal). However, the exit dose to other parts of the patient 
body is also high. 
Photon
25.8 Gy
2.58 Gy
 
 
Figure 3-1 Sagittal slice of the photon absorbed dose distribution for a 4-year-old boy 
from all photon CSI fields. 
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Table 3-2 lists the absorbed doses (minimum, mean and maximum) to the whole 
heart  and sub-structures from photon therapy for each pediatric patient. For heart sub-
structures, the stray photon doses in photon plans were included in the dose exported 
from TPS in this table, as discussed in section 2.4.2. 
 
Table 3-2 Minimum, maximum and mean absorbed dose from therapeutic radiation to 
different heart sub-structures resulting from photon therapy for the population of 
pediatric patients. 
 
Photon absorbed dose (cGy) 
Whole heart Pericardium Myocardium 
 
Patient 
index 
Patient 
Age 
(y) 
Patient 
Sex 
min max mean min max mean min max mean 
1 2 F 123.7 2163  1425  123.7 2165  1295  131.4 2138  1405  
2 4 M 85.7 2112  1231  86.4 2110  1059  90 2090  1172  
3 6 F 65.6 2013  893  65.6 2013  887  67.9 1991  868  
4 8 F 89.2 2144  1150  89.6 2144  1089  89.6 2144  1018  
5 10 F 62.7 2065  1090  60.9 2017  931  62.8 1998  950  
6 3 M 108.7 2104  1341  108.6 2095  1261  115.7 2077  1294  
7 4 M 81.7 2077  1077  82.7 2068  1053  86.4 2052  1008  
8 6 M 65.3 2097  1027  65.4 2096  1036  68.6 2055  964  
9 7.6 M 86.4 2953  1256  87.3 2953  1199  91 2918  1191  
10 9.4 M 57.6 2012  969  57.6 2012  913  60.2 1980  915  
11 12 F 98.2 2032  1166  98.8 2028  1081  102 2008  1089  
12 13 F 69.5 2084  1052  69.4 2085  993  72.6 2053  989  
13 16 F 48.4 2001  779  48.5 1998  768  51.6 1976  728  
14 12 M 76.9 1924  872  77.4 1924  812  79.8 1879  800  
15 13 M 96.9 2703  1146  97.6 2709  1108  100.6 2437  1072  
16 14 M 67.1 2294  916  51.7 2134  764  52.9 2103  764  
17 15 M 51.2 1901  634  51.2 1901  664  54.2 1866  626  
18 16 M 57.3 1888  640  57.3 1889  656  59.6 1795  608  
 
 
Figure 3-2 plots the measured photon stray dose in terms of equivalent dose per 
therapeutic dose (mSv/Gy) as a function of distance from field edge (cm) (Howell 
2011, personal communication), where field edge was defined as the 50% isodose line 
according to ICRU recommendation (ICRU 1993). Data from the measurement were fit 
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with a double-Gaussian curve as a function of distance from field edge (Newhauser 
2011, personal communication).: 
2 2
21
2 2
1 2
( ) ( )
2 2[ (1 ) ]
x x x x
H a ce c eσ σ
− −
− −
= + −                                     (3-1) 
where H is the stray equivalent dose (cSv/Gy). The values a, c, 1x  , 2x , 1σ , 2σ  are 
fitted parameters, and the best fit result is: 
2 2
2 2
( 3.32) ( 2.55)
2 (3.37) 2 (9.66)159.80 e 116.13 e
x x
H
+ +
− −
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Figure 3-2 Values of stray radiation absorbed dose equivalent per therapeutic absorbed 
dose (H/D) as a function of distance from field edge (x). Measured data were taken 
from Howell et al (personal communication).The dashed lines are 95% confidence 
interval of fitting result (Newhauser 2011, personal communication).  
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3.1.3 Dose reconstruction for proton therapy 
Figure 3-3 shows the proton therapeutic absorbed dose distribution for a 
representative pediatric patient. The treatment plan provided adequate coverage of the 
age-specific treatment target. 
Proton
25.8 Gy (RBE)
2.58 Gy (RBE)
 
Figure 3-3 Sagittal slice of the proton absorbed dose distribution for a 4-year-old boy 
from all proton CSI fields. 
 
 
Table 3-3 lists the therapeutic absorbed dose statistics (minimum, mean, and 
maximum) to the whole heart and sub-structures resulting from proton therapy for the 
population of pediatric patients. Note very low doses to the heart from proton CSI for 
patient index 13, 15, 17, 18 (ages are 16, 13, 15, 16). The proton target volume only 
included spinal axis for patients older than 15, whereas for all other patients the proton 
target volume was more anterior because it was designed to cover the entire vertebral 
body. Patient no. 15, who is a 13-year-old boy, also did not have his whole vertebral 
body covered because of his large stature. 
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Table 3-3 Minimum, maximum and mean absorbed doses from therapeutic radiation to 
different heart structures resulting from proton therapy for the population of pediatric 
patients. 
 
Proton therapeutic dose (cGy (RBE)) 
Whole heart Pericardium Myocardium 
 
Patient 
index 
Patient 
Age 
(y) 
Patient 
Sex 
min max mean min max mean min max mean 
1 2 F 0 1157  3.9 0 1127  13.2 0 434  1.2 
2 4 M 0 3001  21.1 0 2949  60.6 0 2419  13.5 
3 6 F 0 1995  12.5 0 1987  30.9 0 1784  8.8 
4 8 F 0 2240  32.5 0 2238  85.3 0 2241  44.4 
5 10 F 0 2127  39.4 0 2126  95.7 0 1961  30.8 
6 3 M 0 1740  61.6 0 1714  109.5 0 1651  51.7 
7 4 M 0 2047  32.1 0 2047  74.9 0 1978  24.3 
8 6 M 0 1597  8.7 0 1560  21.4 0 1303  5.9 
9 7.6 M 0 1873  31.1 0 1873  84.6 0 1596  21.9 
10 9.4 M 0 953  4.9 0 953  15.5 0 665  3 
11 12 F 0 1916  15.4 0 1874  43.2 0 1226  10.9 
12 13 F 0 2184  14.4 0 2184  44.4 0 1982  8.8 
13 16 F 0 249  0.2 0 237  0.6 0 76  0.2 
14 12 M 0 1621  16.6 0 1620  41 0 1375  15.9 
15 13 M 0 0  0.1 0 0  0.1 0 0  0.1 
16 14 M 0 2520  39.7 0 2520  126.3 0 2501  34.1 
17 15 M 0 259  0.3 0 259  1.1 0 123  0.2 
18 16 M 0 0  0.1 0 0  0.1 0 0  0.1 
 
 
Figure 3-4 shows the stray neutron equivalent dose distribution to a pediatric 
patient from proton CSI. Although the stray neutron equivalent dose is much lower in 
magnitude compared to the therapeutic proton dose, it penetrated the whole body of the 
patient and was not negligible. 
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Neutron 0.6 Sv
0.1 Sv
 
Figure 3-4 Sagital slice of the stray neutron equivalent dose (from external and internal 
neutrons from all fields) distribution generated during proton CSI for a 4-year-old boy. 
 
 
 
Table 3-4 lists mean stray neutron dose to the whole heart and sub-structures 
from proton therapy, and Figure 3-5 shows the stray neutron dose to heart sub-
structures as a function of patient’s age. The stray neutron dose to older patients were 
slightly higher than those to younger patients, and there were strong and significant 
correlation between stray neutron dose and patients’ age at exposure (whole heart, 
correlation coefficient r = 0.55, p = 0.018, pericardium, r = 0.57, p = 0.014, 
myocardium, r = 0.56, p = 0.016). The possible reason for higher stray equivalent 
neutron doses to older patients was that older patients have longer spine, so more spinal 
fields (typically 3) were used for older patients versus 1 or 2 spinal fields used for 
younger patients. 
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Table 3-4 Mean stray neutron equivalent dose (H) in the whole heart and sub-structures 
of each patient from proton CSI. 
 
H (mSv)  
Patient
Index 
Patient
Age 
(y) 
Patient
Sex Whole heart Pericardium Myocardium
1 2 F 235.5 238.1 234.8 
2 4 M 259.9 261.0 259.7 
3 6 F 244.6 249.8 244.0 
4 8 F 206.4 244.4 217.7 
5 10 F 298.3 304.2 297.7 
6 3 M 231.6 233.4 231.3 
7 4 M 242.3 245.5 240.9 
8 6 M 276.8 281.5 275.3 
9 7.6 M 228.7 252.9 225.9 
10 9.4 M 262.7 265.9 261.7 
11 12 F 254.7 259.2 254.0 
12 13 F 401.6 415.1 397.1 
13 16 F 262.8 267.4 262.8 
14 12 M 375.2 387.9 375.0 
15 13 M 238.9 241.2 239.6 
16 14 M 376.8 386.1 374.6 
17 15 M 289.9 297.3 288.9 
18 16 M 324.9 336.9 323.8 
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Figure 3-5 Stray neutron equivalent dose HT to the whole heart and sub-structures from 
proton therapy as a function of patient age at exposure, e. 
 
We compared the stray neutron dose generated by proton CSI to those from 
photon dose in photon CSI (Figure 3-6). Close to the field edge, the stray neutron dose 
from proton CSI is much lower than the stray photon dose from photon CSI. Further 
away from field edge, the difference between stray neutron dose and stray photon dose 
became smaller.  This difference in stray dose from proton versus photon CSI was 
indistinguishable beyond 14 cm distance. 
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Figure 3-6 Comparison of stray equivalent dose per therapeutic absorbed dose, H/D, as 
a function of distance from field edge, x, between photon and proton CSI. Measured 
photon stray dose data were taken from Howell et al (in preparation). Stray equivalent 
dose data from proton CSI were from this study. 
 
Overall, the proton treatment plans provided a significant reduction in exit dose 
to normal tissues distal to the target compared to the photon plans (see Figure 3-1 and 
Figure 3-3). Figure 3-7 plots DVHs for therapeutic dose from photon and proton CSI 
plans (Howell et al 2011). Both plans provided good coverage to the treatment target, 
and the superior normal tissue sparing of the proton treatment plan is evident in this 
figure. 
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Dose (cGy (RBE))
 
Figure 3-7 Cumulative DVHs from the treatment plans for a 4-year-old boy (patient 
No. 2) Proton and photon DVHs are indicated by dashed and solid lines, respectively, 
for various organs (This figure was from Howell, personal communication). 
 
The dose to the heart (Figure 3-8) from both proton and photon CSI plans are 
shown here as an illustrative comparison. This figure clearly demonstrates that photon 
CSI resulted in much higher doses to the heart compared to proton CSI. 
The mean therapeutic doses to whole heart, pericardium, and myocardium for 
this population of patients received proton CSI were 185.9. 471.3 and 153.2 mGy 
(RBE); and were 10370, 9760 and 9700 mGy from photon CSI. 
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Figure 3-8 Absorbed dose, D, to the whole heart and sub-structures for proton and 
photon CSI plans as a function of patient’s age at exposure, e.  
 
 
The equivalent total dose (sum of therapeutic dose and stray dose) ratio between 
proton CSI and photon CSI was plotted in Figure 3-9, and there was no correlation 
between dose ratio and patient age (whole heart, r = 0.18; pericardium, r = 0.009; 
myocardium, r = 0.28). Table 3-5,   Table 3-6 and Table 3-7 list the mean, standard 
deviation (SD), SD of the mean, median, minimum, and maximum of dose (sum of 
therapeutic absorbed dose and stray equivalent dose) to the whole heart, pericardium 
and myocardium of the sample patients.  
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Table 3-5 The mean, standard deviation (SD), SD of the mean, median, minimum, and 
maximum equivalent dose (sum of therapeutic dose and stray dose) to the whole heart 
of the sample patients. 
 
Whole heart Statistical 
Parameter Dproton 
(cGy)(RBE) 
Dphoton 
(cGy) 
Dproton/Dphoton 
Mean 
4.64E+01 1.04E+03 4.56E-02 
Standard Deviation 
1.79E+01 2.21E+02 1.61E-02 
Median 
4.40E+01 1.06E+03 4.46E-02 
SD of the mean 
4.23E+00 5.21E+01 3.80E-03 
Minimum 
2.40E+01 6.34E+02 1.93E-02 
Maximum 
8.48E+01 1.42E+03 8.44E-02 
n 18 18 18 
 
 
Table 3-6 The mean, standard deviation (SD), SD of the mean, median, minimum, and 
maximum of equivalent dose (sum of therapeutic dose and stray dose)  to the 
pericardium of the sample patients. 
 
Pericardium Statistical 
Parameter Dproton 
(cGy)(RBE) 
Dphoton 
(cGy) 
Dproton/Dphoton 
Mean 
7.58E+01 9.76E+02 7.86E-02 
Standard Deviation 
4.16E+01 1.91E+02 4.60E-02 
Median 
7.45E+01 1.01E+03 7.29E-02 
SD of the mean 
9.80E+00 4.50E+01 1.08E-02 
Minimum 
2.42E+01 6.56E+02 2.19E-02 
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Maximum 
1.65E+02 1.29E+03 2.16E-01 
n 18 18 18 
 
Table 3-7 The mean, standard deviation (SD), SD of the mean, median, minimum, and 
maximum of equivalent dose (sum of therapeutic dose and stray dose)  to the 
myocardium of the sample patients. 
 
Myocardium Statistical 
Parameter Dproton 
(cGy)(RBE) 
Dphoton 
(cGy) 
Dproton/Dphoton 
Mean 
4.31E+01 9.70E+02 4.61E-02 
Standard Deviation 
1.64E+01 2.18E+02 1.85E-02 
Median 
3.79E+01 9.76E+02 4.24E-02 
SD of the mean 
3.86E+00 5.13E+01 4.36E-03 
Minimum 
2.41E+01 6.08E+02 1.76E-02 
Maximum 
7.48E+01 1.40E+03 9.37E-02 
n 18 18 18 
 
 
The mean equivalent dose ratio values were 0.0456, 0.0786 and 0.0461 for 
whole heart, pericardium and myocardium, respectively. A t test was performed to 
determine if the mean of the total dose ratio values were significantly less than 1, and 
the test results revealed that the proton CSI delivered significantly lower dose to whole 
heart, pericardium and myocardium than did photon CSI (Figure 3-10). 
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Figure 3-9 Dose (therapeutic dose + stray dose) ratio (proton/photon) for the heart sub-
structures as a function of patient age at exposure, e. 
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Figure 3-10  The population-average dose ratio values. The error bars represent the 
standard deviation for each group of data, e.g., whole heart, pericardium and 
myocardium. 
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The equivalent dose to the thyroid (Figure 3-11) from both proton and photon 
CSI plans are also shown here. It is readily apparent that the photon therapy delivered 
much higher doses to the thyroid compared to proton therapy. 
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Figure 3-11 Equivalent Dose (D) to the thyroid for both proton and photon plans, as a 
function of patient’s age at exposure, e. 
 
 
 
3.2 Predicted risk of radiogenic second cancer 
A 4-year-old boy was chosen for risk calculations of radiogenic second cancers 
to facilitate comparison with previous investigations by Miralbell et al (2002) and 
Newhauser et al (2009). Table 3-8 lists mean organ equivalent doses from proton and 
photon radiation treatment plans for a 4-year-old boy (patient index no. 2). For proton 
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CSI, therapeutic and stray equivalent doses are listed, and total equivalent doses are 
also listed. For photon CSI, the total equivalent dose values are listed. The equivalent 
dose to the remainder, which includes any organ for which risk coefficients were not 
explicitly provided by the BEIR VII report, was estimated as the mean equivalent dose 
for the other organs listed in Table 3-8. 
 
Table 3-8 Mean organ equivalent doses from proton and photon CSI plans for a 4-year-
old boy. For proton CSI, both therapeutic and stray doses were listed, and a summation 
of them was also listed. For photon CSI, the combined dose from both therapeutic and 
stray doses was listed. 
 
 
HT, Proton (mSv) 
 
 
Organs 
Therapeutic Stray Total 
HT, Photon 
(mSv) 
Total 
 
HT, Proton, total/ 
HT, Photon, total 
Gonads 1 159 160 1662 0.096 
Colon 165 209 374 6415 0.058 
Lungs 248 329 577 4413 0.131 
Stomach 673 289 962 4076 0.236 
Bladder 5 170 175 3127 0.056 
Liver 171 249 420 5493 0.076 
Thyroid 6 383 389 10854 0.036 
Remainder 181 255 437 5149 0.085 
 
 
 
The therapeutic and stray doses in Table 3-8 were used to estimate organ-
specific radiogenic second cancer risks for this boy. Specifically, the baseline values of 
relative risk are listed in Table 3-9, and they were calculated by using a linear non-
threshold (LNT) dose-risk model from the BEIR VII report (NRC 2006) and the 
neutron radiation weighting factors based on data from Newhauser et al (2009). 
 
Table 3-9 Baseline calculations of relative risk of radiogenic second cancer for a 4-
year-old boy in each organ (RRT), and ratio of relative risk (RRR = RRproton/RRphoton) 
following photon and proton therapies at 15, 30, 45, 60, 75 and 95 years after treatment. 
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 15 years 30 years 45 years 
Organs RRT 
Proton 
RRT 
Photon 
RRproton/ 
RRphoton 
RRT 
Proton 
RRT 
Photon 
RRproton/ 
RRphoton 
RRT 
Proton 
RRT 
Photon 
RRproton/ 
RRphoton 
Stomach 3.204  10.340  0.310  1.976  5.136  0.385  1.585  3.479  0.456  
Colon 3.571  45.101  0.079  2.138  20.527  0.104  1.682  12.706  0.132  
Liver 2.467  20.181  0.122  1.649  9.493  0.174  1.389  6.092  0.228  
Lung 3.015  16.410  0.184  1.892  7.823  0.242  1.535  5.090  0.302  
Prostate 1.210  3.176  0.381  1.093  1.964  0.557  1.056  1.578  0.669  
Bladder 1.955  18.061  0.108  1.423  8.554  0.166  1.253  5.529  0.227  
Thyroid 2.784  50.782  0.055  2.784  50.782  0.055  2.784  50.782  0.055  
Other 7.440  76.878  0.096  2.263  15.876  0.142  1.454  6.347  0.229  
 
 60 years 75 years 95 years 
Organs RRT 
Proton 
RRT 
Photon 
RRproton/ 
RRphoton 
RRT 
Proton 
RRT 
Photon 
RRproton/ 
RRphoton 
RRT 
Proton 
RRT 
Photon 
RRproton/ 
RRphoton 
Stomach 1.403  2.706  0.518  1.300  2.270  0.573  1.219  1.926  0.633  
Colon 1.470  9.055  0.162  1.350  6.998  0.193  1.255  5.373  0.234  
Liver 1.268  4.503  0.282  1.199  3.609  0.332  1.145  2.902  0.395  
Lung 1.368  3.814  0.359  1.274  3.096  0.412  1.200  2.528  0.475  
Prostate 1.038  1.397  0.743  1.028  1.296  0.794  1.021  1.216  0.840  
Bladder 1.174  4.116  0.285  1.130  3.320  0.340  1.095  2.692  0.407  
Thyroid 2.784  50.782  0.055  2.784  50.782  0.055  2.784  50.782  0.055  
Other 1.215  3.531  0.344  1.119  2.404  0.466  1.063  1.746  0.609  
 
The calculated RRR values were always much less than 1 at 15, 30, 45 and 60 
years after exposure. The RRR values increased with attained age. All predicted 
baseline RRR values were less than 1, indicating a lower risk of second cancer 
following proton CSI compared to photon CSI. 
 LAR coefficients were used to calculate the cumulative risk of radiogenic 
second cancer incidence of this patient at an attained age of 100 years (exposed at 4 
years). The cumulative lifetime risk of second cancer following proton CSI was 
estimated at 7.7%, while the risk following photon CSI was 92.0%. The ratio of risks 
from proton and photon therapies is 0.083 (95% confidence interval is 0.081-0.085). 
The cumulative lifetime risk of second cancer incidence following proton therapy is 
4.5% from therapeutic radiation and 6.1% from stray radiation. (Due to the 
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methodology used to calculate photon absorbed dose, it was not possible to separate 
therapeutic dose from stray dose in photon CSI). 
 
3.3 Predicted risk of cardiac toxicity 
 Figure 3-12 shows the therapeutic dose distributions to the heart from photon 
and proton treatment plans for a 4-year-old boy (patient index No.2). Obviously, the 
primary proton beams provided much lower exist dose to the heart. Taking the 
secondary neutron dose from proton therapy into account, the mean organ doses to the 
whole heart and sub-structures were listed in Table 3-10. Again, the proton therapy plan 
provided much lower mean radiation dose to the heart. 
DVHs for heart sub-structures for this patient were exported from TPS and 
Figure 3-13 shows differential DVHs for photon and proton plans. For the photon 
plans, the DVHs were obtained from TPS directly; for the proton plans, the DVHs for 
primary dose were obtained from TPS, then a mean neutron equivalent dose was added 
uniformly to the primary DVH assuming the secondary neutron dose is uniformly 
distributed. Again, the photon plan delivered higher dose to the heart sub-structures 
compared to the proton plan.    
 52 
25.8 Gy (RBE)
2.58 Gy (RBE)
25.8 Gy
2.58 Gy
Proton
Photon
 
 
Figure 3-12 Axial (left) and sagittal (right) slices of absorbed dose distribution from 
the photon plan (top) and the proton plan (bottom) for a 4-year-old boy receiving CSI. 
 
 
Table 3-10 Mean organ equivalent dose to heart sub-structures from proton and photon 
plans for a 4-year-old boy receiving CSI. 
 
Proton therapy dose   
Organ DT  
(Gy (RBE)) 
HT  
(Sv) 
Total 
(Sv) 
Photon 
HT(Sv) 
Dose ratio 
(proton/photon) 
Pericardium 0.61 0.26 0.87 10.59 0.08 
Myocardium 0.14 0.26 0.40 11.72 0.03 
Whole heart 0.21 0.26 0.47 12.31 0.04 
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Figure 3-13 Differential DVHs of heart sub-structures from (a) proton (b) and photon 
CSI treatment plans (therapeutic + stray radiation doses) for a 4-year-old boy. 
 
 
Table 3-11 lists the calculated NTCP values of the whole heart and its sub-
structures for this patient based on DVHs from photon and proton plans and baseline 
NTCP model parameters listed in Table 2-2. The predicted RNTCP values were always 
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much less than one regardless of the parameter sets used, which suggests that proton 
CSI would deliver a much lower risk of cardiac toxicity compared to photon therapy. 
 
Table 3-11 NTCP values for heart sub-structures and relative NTCP (RNTCP) values 
based on existing model parameters.  
 
 D50 
(Gy) 
n m γ s NTCPProton 
(%) 
NTCPPhoton 
(%) 
RNTCP 
Pericardium 48 0.35 0.1 - - 0 4.66*10-12 0 
Pericardium 50.6 0.64 0.13 - - 2.98*10-12 4.67*10-8 6.38*10-5 
Pericardium 49.2 - - 3 0.2 0 0 N/A 
Myocardium 52.2 - - 1.25 0.87 9.63*10-7 0.032 3.01*10-5 
Whole heart 52.3 - - 1.28 1 2.00*10-5 0.025 8.00*10-4 
Whole heart 63.3 - - 0.93 1 0.022 0.58 0.0383 
Whole heart 70.3 - - 0.96 1 0.00107 0.31 0.0345 
 
Predicted NTCP values for the population of patients are listed in Table 3-12, 
where the following NTCP parameters were used: pericardium, D50 = 50.6 Gy, n = 0.64 
and m = 0.13; myocardium, D50 = 52.2 Gy, γ = 1.25 and s = 0.87; for the whole heart 
the average of 3 sets of parameters were used: D50 = 62 Gy, γ = 1.06 and s = 1.  
 
Table 3-12 Predicted NTCP values for the whole heart, pericardium and myocardium 
following proton and photon therapies for a population of pediatric patients (n = 18). 
RNTCP=NTCPproton/NTCPphoton. 
 
Proton NTCP(%) Photon NTCP(%) RNTCP 
Whole heart Pericardium Myocardium Whole heart Pericardium Myocardium Whole heart Pericardium Myocardium 
 
 
Index Age Sex 
         
1 
2 F 5.06E-04 1.19E-12 1.39E-07 2.04E-01 2.74E-07 4.80E-02 2.48E-03 4.34E-06 2.90E-06 
2 
4 M 7.82E-04 2.96E-12 7.64E-07 1.52E-01 4.67E-08 3.17E-02 5.14E-03 6.34E-05 2.41E-05 
3 
6 F 9.09E-04 2.15E-12 5.49E-06 8.55E-02 1.28E-08 1.44E-02 1.06E-02 1.68E-04 3.81E-04 
4 
8 F 1.90E-03 5.63E-12 1.85E-04 1.36E-01 3.46E-08 2.72E-02 1.40E-02 1.63E-04 6.80E-03 
5 
10 F 2.00E-03 6.36E-12 3.11E-05 1.13E-01 1.75E-08 1.67E-02 1.77E-02 3.63E-04 1.86E-03 
6 
3 M 1.90E-02 6.22E-12 2.94E-05 1.88E-01 2.40E-07 4.20E-02 1.01E-01 2.59E-05 7.00E-04 
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7 
4 M 2.00E-03 5.10E-12 3.91E-05 1.26E-01 5.32E-08 2.36E-02 1.59E-02 9.59E-05 1.66E-03 
8 
6 M 5.98E-04 1.60E-12 4.23E-07 1.22E-01 5.15E-08 2.25E-02 4.90E-03 3.11E-05 1.88E-05 
9 
8 M 1.02E-03 4.47E-12 2.78E-06 4.28E-01 4.38E-07 2.33E-01 2.38E-03 1.02E-05 1.19E-05 
10 
10 M 5.13E-04 1.27E-12 1.52E-07 9.60E-02 1.57E-08 1.63E-02 5.34E-03 8.09E-05 9.33E-06 
11 
12 F 6.53E-04 2.20E-12 3.11E-07 1.24E-01 5.17E-08 2.20E-02 5.27E-03 4.26E-05 1.41E-05 
12 
13 F 1.20E-03 3.23E-12 7.88E-06 1.21E-01 3.26E-08 2.30E-02 9.92E-03 9.91E-05 3.43E-04 
13 
16 F 4.97E-04 1.01E-12 1.43E-07 6.01E-02 4.32E-09 8.50E-03 8.27E-03 2.34E-04 1.68E-05 
14 
12 M 7.21E-04 2.42E-12 1.31E-06 5.27E-02 4.39E-09 5.67E-03 1.37E-02 5.51E-04 2.31E-04 
15 
13 M 4.06E-04 9.33E-13 1.11E-07 1.40E-01 1.05E-07 2.76E-02 2.90E-03 8.89E-06 4.02E-06 
16 
14 M 6.87E-03 1.69E-11 7.52E-04 1.11E-01 5.19E-09 1.38E-02 6.19E-02 3.26E-03 5.45E-02 
17 
15 M 5.05E-04 1.05E-12 1.48E-07 3.79E-02 1.51E-09 4.40E-03 1.33E-02 6.95E-04 3.36E-05 
18 
16 M 4.37E-04 1.04E-12 1.28E-07 2.67E-02 1.02E-09 2.24E-03 1.64E-02 1.02E-03 5.71E-05 
 
Table 3-13, Table 3-14 and Table 3-15 list the mean, standard deviation (SD), 
SD of the mean, median, minimum, maximum of predicted NTCP values for the whole 
heart, pericardium and myocardium, respectively, of the sample of patients.  
 
Table 3-13 The mean, standard deviation (SD), SD of the mean, median, minimum, 
maximum of NTCP values for the whole heart of the sample of patients. 
 
Whole heart Statistical 
Parameter NTCPproton (%) NTCPphoton (%) RNTCP 
Mean 
2.25E-03 1.29E-01 1.73E-02 
Standard Deviation 
4.44E-03 8.82E-02 2.48E-02 
Median 
7.52E-04 1.22E-01 1.03E-02 
SD of the mean 
1.05E-03 2.08E-02 5.85E-03 
Minimum 
4.06E-04 2.67E-02 2.38E-03 
Maximum 
1.90E-02 4.28E-01 1.01E-01 
n 18 18 18 
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Table 3-14 The mean, standard deviation (SD), SD of the mean, median, minimum, 
maximum of NTCP values for the pericardium of the sample of  patients. 
 
Pericardium Statistical 
Parameter NTCPproton (%) NTCPphoton (%) RNTCP 
Mean 
3.65E-12 7.72E-08 3.84E-04 
Standard Deviation 
3.81E-12 1.19E-07 7.69E-04 
Median 
2.31E-12 3.36E-08 9.75E-05 
SD of the mean 
8.98E-13 2.81E-08 1.81E-04 
Minimum 
9.33E-13 1.02E-09 4.34E-06 
Maximum 
1.69E-11 4.38E-07 3.26E-03 
n 18 18 18 
 
Table 3-15 The mean, standard deviation (SD), SD of the mean, median, minimum, 
maximum of NTCP values for the myocardium of the sample of patients. 
 
Myocardium Statistical 
Parameter NTCPproton (%) NTCPphoton (%) RNTCP 
Mean 
5.87E-05 3.24E-02 3.70E-03 
Standard Deviation 
1.78E-04 5.15E-02 1.28E-02 
Median 
1.04E-06 2.23E-02 4.54E-05 
SD of the mean 
4.21E-05 1.21E-02 3.01E-03 
Minimum 
1.11E-07 2.24E-03 2.90E-06 
Maximum 
7.52E-04 2.33E-01 5.45E-02 
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n 18 18 18 
 
Figure 3-14 shows the RNTCP values for the population of patients as a 
function of age at exposure. Figure 3-15 plots the predicted RNTCP values for males 
and females separately to check if there is any sex-dependency. The RNTCP values 
were much less than one, regardless of patient’s age and sex. There was no significant 
association between predicated RNTCP values and age at exposure (whole heart, 
correlation coefficient r = 0.14, p = 0.59, pericardium, r = 0.43, p = 0.07, myocardium, 
r = 0.21, p = 0.40), and the RNTCP values were independent of sex (t test for equal 
means: whole heart, p = 0.34, pericardium, p = 0.41, myocardium, p = 0.55; Wilcoxon 
rank sum test for equal medians: whole heart, p = 0.86, pericardium, p = 0.66, 
myocardium, p = 0.60).  
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Figure 3-14 Predicted RNTCP values for a population of patients as a function of 
patient’s age at exposure. 
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Figure 3-15 Predicted RNTCP values versus age at exposure, e, by sex for a sample of 
patients (n=18) for which proton and photon CSI treatment plans were prepared. 
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There are strong and significant correlations between the organ dose ratio and 
RNTCP values (Figure 3-16) (whole heart, correlation coefficient r = 0.66, p = 0.003, 
pericardium, r = 0.69, p = 0.001, myocardium, r = 0.69, p = 0.002), which indicates the 
radiation dose to the heart is the governing factor for risk of cardiac toxicities. 
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Figure 3-16 RNTCP VS mean organ dose ratio (Dproton/Dphoton) for heart sub-structures 
for a population of pediatric patients. 
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The averaged predicted RNTCP values were 1.66×10-2, 3.46×10-4  and 3.70×
10-3 for whole heart, pericardium and myocardium, respectively (Figure 3-17). The t 
test and sign test were performed to determine if the mean and the median of the 
RNTCP values were significantly less than 1. The RNTCP values were shown to be 
statistically significantly less than 1 for the whole heart, myocardium and pericardium. 
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Figure 3-17  The population-average RNTCP values. The error bars represent the 
standard deviation of RNTCP values for each group of data, e.g., whole heart, 
pericardium and myocardium. 
 
 
 
 
3.4 Sensitivity of predicted risk of second cancer to modeling assumptions 
 
The baseline risks of radiogenic second cancer were calculated based on the 
assumptions embodied in the LNT models from the BEIR VII report and mean 
radiation weighting factors for neutrons, Rw , based on recommendations of ICRP 
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Publication 92. Because of the large uncertainties associated with those methods, 
sensitivity tests were performed to examine how sensitive the final risk values were to 
those aspects of dose and risk modeling 
Table 3-16 lists the lifetime risks in each tissue (LART), sum of LART values 
over all tissues (LARmodality) and the ratio of LARproton to LARphoton (RLAR) for various 
scaling factors (0.5, 2, 5, 10, 20, 25) of the mean neutron radiation weighting factor 
( Rw ). As the mean neutron radiation weighting factor increased, the LAR values for 
proton therapy increased, and the final RLAR values also increased because it increased 
the stray neutron equivalent dose from proton therapy. The total dose in photon therapy 
remained the same because there was no neutron dose generated in 6 MV photon 
beams. 
 
Table 3-16 Predicted relative risk (15 years after exosure) in each tissue (LART) and the 
ratio of LARproton to LARphoton (RLAR) for various scaling factors of the radiation 
weighting factor ( Rw ) for neutrons.  
 
 LART (%) 
 Nominal Rw  Rw /2 Rw *2 Rw *5 
Organs Proton Photon Proton Photon Proton Photon Proton Photon 
Stomach 0.65  2.73  0.55  2.73  0.84  2.73  1.42  2.73  
Colon 1.10  18.92  0.80  18.92  1.72  18.92  3.57  18.92  
Liver 0.22  2.87  0.16  2.87  0.35  2.87  0.74  2.87  
Lung 1.57  12.00  1.12  12.00  2.46  12.00  5.15  12.00  
Prostate 0.13  1.38  0.067  1.38  0.27  1.38  0.66  1.38  
Bladder 0.32  5.72  0.17  5.72  0.63  5.72  1.57  5.72  
Thyroid 0.33  9.12 0.17  9.12 0.65  9.12 1.61  9.12 
Other 3.33  39.23  2.36  39.23  5.27  39.23  11.11  39.23  
         
RLAR 0.083  0.058  0.13  0.28 
 
 
 LART 
 
Rw *10 Rw *20 Rw *25 
Organs Proton Photon Proton Photon Proton Photon 
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Stomach 2.39  2.73  4.32  2.73  5.29  2.73  
Colon 6.65  18.92  12.82  18.92  15.90  18.92  
Liver 1.39  2.87  2.69  2.87  3.34  2.87  
Lung 9.62  12.00  18.57  12.00  23.05  12.00  
Prostate 1.32  1.38  2.64  1.38  3.30  1.38  
Bladder 3.12  5.72  6.23  5.72  7.79  5.72  
Thyroid 3.22  9.12 6.44  9.12 8.05  9.12  
Other 20.85  39.23  40.31  39.23  50.04  39.23  
       
RLAR 0.53 1.02 1.27 
 
 
 
The relationship between predicted RLAR values and the maximum weighting 
factor for neutrons is shown in Figure 3-18, revealing that the maximum neutron 
weighting factor would have to be more than 20 times larger (corresponding to a 
maximum wR value of more than 400) than the values in ICRP Publication 92 in order 
for the risk of radiogenic second cancer following proton CSI to exceed that following 
photon CSI. The ICRP Publication 92 (2003) recommended the maximum neutron 
radiation weighting factor was 20. A recent reanalysis of atomic bomb survivors data 
deduced that the 95% confidence interval of neutron RBE was 25~400 (Kellerer et al 
2006). This indicates that proton CSI  reduced the predicted risk of second cancer 
compared to photon CSI for this pediatric patient, regardless of the change of the 
neutron dose in a possible range (5~400).  
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Figure 3-18 Sensitivity of the RLAR values to changes in the maximum radiation 
weighting factor for neutrons. 
 
 
Evidence from CCSS strongly suggests that the dose-risk relationship for 
thyroid is not linear due to cell killing mechanism (Sigurdson et al 2005, Ronckers et al 
2006, Bhatti et al 2010). Therefore the sensitivity of the baseline risk calculation, which 
utilized an LNT model,  for thyroid to change in dose-risk model was examined using 
linear-exponential models, linear-plateau models with different inflection points (Figure 
3-19), as discussed in section 2.7. Neutron radiation weighting factors were based on 
ICRP Publication 92 recommended wR(E) function and Monte Carlo simulated energy-
dependent neutron fluence Ф(E) (Newhauser et al 2009) were used in the calculations. 
Because the exit dose to thyroid in proton plan for this patient (a 4-year-old boy, patient 
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index no. 2) was less than 1.1 Gy (RBE) and the LNT model is recommended for the 
dose range 0~2.5 Sv, the different dose-risk models were only tested for photon plan, 
where the thyroid (exist) dose was much larger than 2.5 Sv.  
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Figure 3-19 Excess relative risk as a function of equivalent dose, H. (LEXP = linear-
exponential; LPLA = linear-plateau) used in this work to estimate excess relative risk 
(ERR) in the thyroid. The numbers in the legend refer to the location of the 
approximate point beyond which risk decreases or plateaus. 
 
Table 3-17 lists the predicted RR and RRR values for each of the thyroid risk 
models studied. The RR values in photon CSI showed substantial sensitivity to the 
selected risk model. Dose-risk models with the low dose roll-off points suppressed the 
risk from high doses, thus reducing the RR value from photon CSI, while increasing the 
RRR value since the RR value from proton CSI was not changed (sensitivity tests were 
only used for photon CSI). However, the predicted RRR values were still less than 1, 
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ranging from 0.055 to 0.36, suggesting that proton CSI confers lower risk of second 
cancer of the thyroid compared to that from photon CSI for this pediatric patient, 
regardless of the cell sterilization effect showing in alternative dose-risk models, e.g., 
linear-plateau model and linear-exponential model. 
 
Table 3-17 The predicted RR and RRR values in thyroid for various dose-risk models 
plotted in Figure 3-19. The dose-risk models include: linear non-threshold (LNT); 
linear-exponential (LEXP); linear-plateau (LPLAT). The numbers in the parenthesis 
indicate the dose at which the model rolls off the risk due to the cell sterilization effect. 
 
RR  Dose Risk 
Model Proton Photon RRR 
LNT 2.78 50.81 0.055 
LEXP (5) 2.78 7.65 0.36 
LEXP (15) 2.78 22.79 0.12 
LEXP (25) 2.78 30.89 0.09 
LEXP (35) 2.78 35.24 0.079 
LPLAT (5) 2.78 8.63 0.32 
LPLAT (15) 2.78 20.31 0.14 
LPLAT (25) 2.78 26.33 0.11 
LPLAT (35) 2.78 29.10 0.096 
 
 
3.5 Sensitivity of predicted risk of cardiac toxicity to modeling assumptions 
 
The baseline risks of radiogenic cardiac toxicity were calculated using NTCP 
models, model parameters from the literature, and nominal neutron radiation weighting 
factors from ICRP Publication 92. However, there are large unknown uncertainties 
associated with those aspects of the risk calculations. Sensitivity tests were performed 
to explore how sensitive the final RNTCP values were to those uncertainties. 
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Figure 3-20 plots RNTCP for the whole heart, myocardium and pericardium 
using various NTCP model parameters. The Lyman model was tested for the 
pericardium, while RS model was tested for the myocardium and the whole heart. For 
the pericardium, the RNTCP values were not sensitive to changes in n values, while the 
RNTCP values were more sensitive to changes in D50 values and very sensitive to 
changes in m values (as m increased from 0.1 to 1, the RNTCP increased substantially). 
For the myocardium and the whole heart, the RNTCP values were not sensitive to 
changes in D50 and s values, while the RNTCP values were very sensitive to changes in 
γ values (as γ increased from 0.1 to 2, the RNTCP decreased substantially). 
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Figure 3-20 Surfaces of predicted RNTCP values for heart sub-structures as functions 
of different NTCP parameters. (Upper) The surfaces displayed were calculated for m 
values of 0.1, 0.3, 0.5 and 1 (pericardium), γ values of 0.1, 0.5, 1 and 2 (myocardium 
and whole heart). (Lower)The surfaces displayed were calculated for n values of 0.1, 
0.3, 0.5 and 1 (pericardium), s values of 0.1, 0.5 and 1 (myocardium and whole heart). 
Color interpolated to facilitate visualization. 
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Based on the results plotted Figure 3-20, the following combinations were 
selected to estimate the minimum and maximum RNTCP values for the pericardium 
(min: D50 = 10 Gy, n = 1, m = 0.05, max: D50 = 90 Gy, n = 0.12, m = 0.5), the 
myocardium (min: D50 = 10 Gy, γ = 3, s = 0.1, max: D50 = 90 Gy, γ = 0.1, s = 1), and 
the whole heart (min: D50 = 10 Gy, γ = 3, s = 0.1, max: D50 = 90 Gy, γ = 0.1, s = 1). The 
intervals for the NTCP model parameters were set large enough to include all published 
values from the literature. The NTCP calculations were done for two patients (a 4-year-
old boy, patient index no. 2 and a 14-year-old boy, patient index no. 16), and the results 
were listed in Table 3-18. The RNTCP values were always less than 1. Considering the 
expansive interval of NTCP model parameters which include the large underlying 
uncertainties associated with NTCP models, and the substantial differences in the dose 
distributions from proton vs. photon CSI, the results of this work strongly suggest that 
proton CSI carries a significantly lower risk of cardiac toxicity compared to photon 
CSI. 
 
Table 3-18 NTCP and RNTCP values of cardiac toxicity for a 4-year-old boy and a 14-
year-old boy using combinations of NTCP model parameters. 
 
RNTCP 
 
Patient index 
 
Age at 
exposure 
(y) Structure Min 
Baseline 
Max 
2 4 Pericardium 0 6.34E-05 0.70 
  Myocardium 9.58 x 10-27 2.41E-05 0.98 
  Whole heart 1.99 x 10-19 5.14 x 10-3 0.97 
16 14 Pericardium 0 3.26 x 10-3 0.99 
  Myocardium 2.58E-05 5.45 x 10-2 0.99 
  Whole heart 1.03 x 10-10 6.19 x 10-2 0.98 
 
 
The relationship between RNTCP values and the neutron wR scaling factor is 
plotted in Figure 3-21, revealing that the RNTCP values were always much less than 1 
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for plausible values (5~40) (BEIR VII, 2006) of the radiation weighting factor for 
neutrons. This suggests that proton CSI confers a lower risk of cardiac toxicity 
compared to photon CSI, regardless of the change of the max radiation weighting factor 
for neutrons in a plausible range.  
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Figure 3-21 Sensitivity of the predicted RNTCP values to changes in the neutron 
radiation weighting factor (wR) for the (a) pericardium, (b) myocardium and (c) whole 
heart. 
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The contouring of the heart sub-structures involves large uncertainties. The 
methods for radiographic identification and delineation of the heart sub-structures is not 
standardized and challenging, and the knowledge of the uncertainty in the contouring is 
incomplete (Gagliardi et al 2010). Various methods for the heart sub-structures have 
been reported (Martel et al 1998, Gagliardi et al 2001, Wei et al 2008).  
                
(a) (b) 
Figure 3-22 Heat sub-structures contouring: (a) baseline contouring (b) revised 
contouring. 
 
 
The sensitivity tests were performed to see how sensitive the risk calculations 
would be to the changes in how the heart was contoured. To accomplish this, the 
pericardium was redefined as a 1 cm shell (i.e., 5 times thicker than that in baseline 
calculations) inside the external heart surface, and the myocardium was redefined as a 1 
cm shell inside the inner surface of pericardium (Figure 3-22). The NTCP calculations 
were carried out for two patients, and the results are listed in Table 3-19. The predicted 
RNTCP values were much less than 1. This further suggests that proton CSI confers a 
significantly lower risk of cardiac toxicity compared to photon CSI, regardless of 
variations in the methods used to contour the heart and its sub-structures. 
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Table 3-19 Predicted NTCP and RNTCP values of cardiac toxicity for a 4-year-old boy 
and a 14-year-old boy based on modified contours. 
 
 
 
 
Patient 
index 
Age at 
exposure 
(y) Structure 
RNTCP 
(Revised 
cardiac 
contours) 
RNTCP 
(Baseline) 
2 4 Pericardium 1.85E-05 6.34E-05 
  Myocardium 4.0 x 10-6 2.41E-05 
16 14 Pericardium 9.4 x 10-4 3.26 x 10-3 
  Myocardium 1.36E-05 5.45 x 10-2 
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4. DISCUSSION 
The goals of this work were to estimate the dose to tissues and organs from 
contemporary craniospinal proton and photon irradiation based on treatment planning 
system calculations, Monte Carlo simulations, and measurements; to calculate the 
corresponding predicted risk of radiogenic second cancer and cardiac toxicity using 
existing dose-risk models; to estimate the uncertainties in the calculated risks, and to 
test for statistical significance in the difference between the calculated risk of radiation 
induced late effects. The results show that proton CSI confers lower predicted risks of 
radiogenic second cancer for the one pediatric patient considered, and lower risks of 
radiogenic cardiac toxicities for the entire population of pediatric patients considered 
(n=18), compared to photon CSI. An uncertainty analysis including sensitivity tests 
reinforced the qualitative findings from the baseline calculations. The major results of 
this study are summarized in sections 4.1 through 4.3 for the reader’s convenience. 
Sections 4.4 through 4.8 discuss the coherence of this study with existing literature, 
implications and significance of this work, strengths and limitations of this work and 
possible future work. 
4.1 Outcomes of specific aim one 
Specific aim one predicted the ratio of relative risk (RRR) and ratio of lifetime 
risk (RLAR) of radiogenic second cancer incidence for one pediatric medulloblastoma 
patient treated with proton CSI vs. photon CSI using the prevailing standards of care at 
our institution. The predicted RRR for a 4-year-old boy was always less than 1 at 15, 
30, 45, 60, 75, 95 years after exposure. The predicted RRR values increased with the 
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time since exposure because competing non-radiogenic risk factors play an increasing 
role as patient age, and thus the predicted ratio of radiogenic risks after proton vs. 
photon CSI decrease in importance with time. The lifetime risks of second cancer 
incidence for this patient were 7.7% and 92% after proton CSI and photon CSI, and 
RLAR is 0.083. The fact that the RRproton and LARproton were much lower than the 
corresponding RR
 photon and LARphoton (about 10 times lower) strongly suggests that 
proton CSI would confer a much lower predicted risk of radiogenic second cancer to 
this pediatric patient compared to photon CSI, and indicates that the same may be true 
for all pediatric patients undergoing CSI. 
4.2 Outcomes of specific aim two 
 
Specific aim two predicted the ratio of normal tissue complication probability 
(RNTCP) of radiogenic cardiac toxicity for a population of pediatric medulloblastoma 
patients treated with proton CSI vs. photon CSI using prevailing standards of care at our 
institution. The mean RNTCP values for the whole heart, pericardium and myocardium 
for the whole population were 1.66×10-2, 3.46×10-4  and 3.70×10-3. Statistical tests 
on the distributions of the risks of radiogenic cardiac toxicity revealed that the predicted 
risks after proton CSI were statistically significantly lower than those after photon CSI.  
The RNTCP values did not reveal a significant dependence on the patients’ age at 
exposure and sex. A strong correlation was found between organ dose ratio (proton to 
photon) and RNTCP values, which confirms the working hypothesis that the lower 
heart dose delivered from proton CSI is one of the major reasons for its lower risk of 
predicted cardiac toxicity compared to photon CSI.  
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4.3 Outcomes of specific aim three 
 
Specific aim three estimated the uncertainty in the calculated RRR, RLAR and 
RNTCP values (proton vs. photon CSI) for the population of medulloblastoma patients, 
taking into account dosimetric uncertainties and variations in variables, including the 
dose-risk model and the mean radiation weighting factor for neutrons ( Rw ). Sensitivity 
tests were carried out by using various scaling factors for Rw  values, various 
modifications to dose-risk models for second cancer risk to take into account cell 
sterilization effects, various NTCP model parameters, and variations in the contours 
that defined the heart. 
The predicted RLAR values were sensitive to the uncertainties in the Rw  values. 
However, the estimated risk of radiogenic second cancer following proton CSI was 
lower than that for photon CSI as long as the maximum radiation weighting factor was 
less than 400. On the assumption that the maximum neutron radiation weighting factor 
is 20, following recommendation in ICRP Publication 92, the calculated risk of 
radiogenic second cancer following proton CSI was 10 times lower than that following 
photon CSI. Interestingly, the RRR values were more sensitive to the change of Rw  
values for shorter time since exposure than for longer time since exposure because there 
were smaller competing non-radiogenic risk factors. The RLAR values for the thyroid 
were sensitive to the changes in the risk model related to cell sterilization effects, and 
an examination of the predicted RRR values for a 4-year-old boy revealed an interval of 
RRR results from 0.055 to 0.36 over 9 variations of the risk models.  
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The RNTCP values for cardiac toxicity were sensitive to the uncertainties in the 
mean radiation weighting factor for neutrons. However, the RNTCP values were always 
much less than one using a wide variety of Rw  values, e.g., from 0.5 to 10 times of 
ICRP Publication 92 recommended value, covering the plausible interval of Rw  values. 
The RNTCP values were very sensitive to m value in Lyman model and to γ value in RS 
model, which can be explained by the models’ inherent properties: The γ value in RS 
model represents the maximum relative slope of the dose-response curve, and the m 
value in Lyman model is inversely proportional to the slope of dose-response curve. 
For these reasons, a change in γ value or m value can make a small change in dose 
induce a large change in normal tissue complication probability, which makes the 
difference between different radiation treatment modalities more pronounced. The 
RNTCP values were not sensitive to changes in n values and D50 values in Lyman 
model, nor were they sensitive to s values and D50 values in RS model. Based on those 
findings, combinations of NTCP model parameters were chosen to bound the range of 
possible model parameter sets, and the corresponding predicted RNTCP values were 
always less than 1 (interval from 0 to 0.993). Hence the predicted risks of radiogenic 
cardiac toxicity following proton CSI were less than that following photon CSI for all 
18 patients in the study, regardless of the selection of the NTCP model parameters in 
plausible ranges, which were taken from the literature. A sensitivity test of the contours 
of the heart sub-structures revealed the calculated RNTCP values were still much less 
than one for all contouring methods that were considered in this work. 
 
 78 
4.4 Coherence with existing literature 
We compared our results with literature. In a previous study, Newhauser et al 
(2009) estimated the risk of radiogenic second cancer following CSI using photon 
versus proton radiotherapies for CSI of a 3-year-old boy. They reported predicted 
lfetime risks of second cancer incidence for the boy at 5.1% for passively-scattered 
proton therapy and 54.8% for conventional photon therapy following 36 Gy CSI. As 
reported in section 3.2, this study estimated the lifetime risk of second cancer at 7.7% 
following proton therapy and 92.0% following photon therapy for a 4-year-old boy 
received 23.4 Gy CSI. If normalized to the same prescribed dose, the lifetime second 
cancer incidence in our work is about 2.3 times higher than that in their work (Table 
4-1).  
Table 4-1 Comparison of lifetime risk (prescribed dose 23.4 Gy) of second cancer 
incidence and ratio of the lifetime risk between proton CSI and conventional photon 
CSI (CRT) from different studies.  
 
Lifetime risk (%)  
CRT Proton 
RLAR 
(CRT/proton)
 
Miralbell et al (2002) 35.6 2.4 15 
Newhauser et al (2009) 35.6* 3.3 11 
This work 92.0 7.7 12 
*Value taken from Miralbell et al (2002) 
 
Considering stray neutron dose only, Newhauser et al (2009) reported 1.5% 
lifetime risk of second cancer incidence, while we predicted 4.6% lifetime risk of 
second cancer incidence. If normalized to the same prescribed dose, our result is about 
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4.7 times higher than their result. There are several possible reasons why our result is 
higher than theirs:  
First, different dose-risk models were used in their and our studies. ICRP 
Publication 60 (1990), which was published for radiation protection purpose and 
provided sex-averaged and age (age at exposure or attained age) non-specific risk 
coefficients, was used in their study. BEIR VII report, which utilized more recent and 
detailed epidemiological data and contained organ, sex, age specific coefficients, was 
used in our study. Table 4-2 lists the risk coefficients for lifetime second cancer 
incidence rate from ICRP Publication 60 (ICRP 1990) (attained age at 76 years) and 
BEIR VII (NRC, 2006) (attained age at 100 years). From Table 4-2, we can see that the 
risk coefficients from BEIR VII for the patient we studied (a 4-year-old boy) are 
generally higher than those from ICRP Publication 60, since a young patient is more 
prone to have radiogenic second cancer compared to the general population. If we took 
the sex-averaged risk coefficients from BEIRVII for patient who is 30 years old (the 
8th column of Table 4-2), the coefficients are much closer to the risk coefficients from 
ICRP Publication 60. The other significant difference between those two reports is that 
BEIR VII report excluded skin cancer from the risk model because the special 
properties of skin cancer (NRC, 2006). However, the incidence of skin cancer in 
childhood cancer survivors was large (Meadows et al 2009). Based on these 
observations, if we roughly adjusted the risk values from Newhauser et al by age and 
sex (multiplying the risk coefficient from ICRP 60 by the ratio between 3rd column and 
8th column of Table 4-2), the lifetime risk of second cancer incidence would be 106.1 
and 9.5 after photon and proton CSI, which are very close to the risk values from this 
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work. Therefore, after we adjusted the dose-risk coefficient values by age and sex so 
that the risk models were similar, we had similar values to those of Newhauser et al 
(2009). 
Table 4-2 Risk coefficients for lifetime second cancer incidence from ICRP Publication 
60 (ICRP 1991) and BEIR VII (NRC, 2006). 
 
Lifetime risk (%/Sv) 
BEIR VII 
 
 
Organ 
 
 
ICRP 60 
4-year-old  
male 
4-year-old 
female 
4-year-
old sex 
average 
30-year-
old  
male 
30-year-
old 
female 
30-year-
old sex 
average 
Stomach 1.22 0.67 0.88 0.78 0.28 0.36 0.32 
Colon 1.55 2.95 1.90 2.45 1.25 0.82 1.04 
Liver 0.16 0.52 0.24 0.38 0.22 0.10 0.16 
Lung 0.90 2.72 6.33 4.53 1.05 2.42 1.74 
Breast 0.40 - 9.65 4.83 - 2.53 1.27 
Ovary or 
Prostate 0.14 0.83 0.90 0.87 0.35 0.50 0.43 
Bladder 0.60 1.83 2.12 1.98 0.79 0.79 0.79 
Thyroid 0.80 0.84 4.62 2.73 0.09 0.41 0.25 
Skin 10.0 - - - - - - 
Leukemia 0.51 1.67 1.27 1.47 0.84 0.63 0.74 
Other 0.70 7.62 13.40 10.51 0.20 0.21 0.21 
 
Second, they did not account for the underestimation in out-of-field dose from 
photon therapy, i.e., they used photon data from Miralbell (2002), which were taken 
from a TPS. The TPS can underestimate out-of-field photon dose and on average the 
organ doses from TPS could be about 30% lower than those measured for out-of-field 
organs (Howell et al 2010a). 
Third, Newhauser et al used a stylized adult phantom, which is less realistic 
than the patient CT image based voxelized phantom used in this study, in their study to 
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represent the pediatric patient, and they put spherical dose receptors inside the phantom 
and used the mean dose in the receptors to represent the mean organ dose. Those 
affected the neutron doses (Table 4-3).  
Good agreement was found between our study and theirs regarding the ratio of 
lifetime risk for second cancer incidence after proton and photon CSI (Table 4-1). 
Specifically, they reported 0.097 versus 0.083 from this work. Given the differences in 
methods used for risk calculations, as discussed above, the ratio of risk values are 
remarkably similar. The possible reason is that although different methods were used in 
different studies, using the ratio of risk values as a figure of merit cancels some sources 
of uncertainty, like uncertainties associated with risk models. Thus, the ratio of the risk 
is an advantageous “figure of merit” for treatment modality comparison research, as 
long as the methods used are consistent within one comparative study. 
More recently, Taddei et al (2010c) estimated lifetime risk of second cancer 
incidence and mortality for a boy and a girl due to stray neutron dose from proton CSI 
with 23.4 Gy (RBE) prescription. Their risk value for the 10-year-old boy was 8.5% 
lifetime incidence. Bone marrow and skin were included in their calculation, while this 
work did not take those two tissues into account. After subtracting second cancer risks 
from those two tissues, their lifetime risk value for the boy was 5.5%, which agrees 
well with our lifetime risk value 4.6% due to stray neutrons, although still higher 
considering the difference in the age of patients being studied. Normally younger 
patients should have increased risk values because of increased sensitivity and higher 
dose due to smaller bodies. The most likely reason for their higher risk values is 
because smaller air gap (2 cm) for spinal fields were used in Taddei et al  for the 10-
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year-old boy, while around 12 cm air gap (Table 2-1) were used in this work for the 4-
year-old boy. So the neutron doses from Taddei et al were higher than this work (Table 
4-3). Table 4-3 lists the stray organ doses in terms of equivalent dose per therapeutic 
dose (mSv/Gy) from proton CSI from different studies. The neutron doses from 
Newhauser et al (2009) were lower than those from Taddei et al (2009) and current 
study because of different dose recording techniques, and the HT/D values from Taddei 
et al (2009) were higher than that from current study because they used smaller air gap 
for spinal fields. 
 
Table 4-3 Comparison of stray organ doses from proton CSI between different studies. 
 
HT/D (mSv/Gy)  
Organs Current study Taddei 
(2009) 
Newhauser 
(2009) 
Gonads 6.8 4.5 0.8 
Colon 8.9 15.4 4.7 
Lungs 14.1 28.1 8.0 
Stomach 12.4 19.8 5.9 
Bladder 7.3 6.7 1.4 
Liver 10.6 20.7 5.7 
Thyroid 16.4 31.6 12.3 
Remainder 10.9 16.1 4.8 
 
A research group at Massachusetts General Hospital estimated stray neutron-
induced risk of second cancer for patients received brain fields (Zacharatou Jarlskog 
and Paganetti 2008) and spinal field (Athar and Paganetti 2009). They reported lifetime 
risk of second cancer incidence less than 1% due to stray neutron dose in most cases. It 
is hard to directly compare their results with ours because of the large differences in the 
treatment technique and dose simulation method. They did not investigate clinically 
approved CSI plans, but using generic circular proton fields for hypothetical tumors. 
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Equivalent doses from stray radiation from photon CSI and proton CSI were 
compared in this study (Figure 3-6), revealing that the stray neutron dose from proton 
CSI was much lower than the stray photon dose from photon CSI close to the field edge, 
while the difference became smaller further away from field edge. Proton and photon 
CSI generated roughly same amount of stray dose at larger distance (beyond 14 cm). 
Athar et al (2010) recently compared out-of-field photon dose from 6 MV IMRT and 
stray neutron dose from proton therapy in the head and neck and spine region, and their 
finding was different from ours. They basically divided stray radiation into three 
geometrical areas: proton therapy offered a lower integral dose in the therapeutic field; 
the stray neutron dose was a factor 2 higher than stray photon dose within ~ 25 cm from 
the therapeutic field edge but out of therapeutic field; and proton therapy generated a 
factor of 2~3 factor lower dose at larger distances to the therapeutic field compared to 
IMRT. The possible reasons for this discrepancy include: first, different photon 
treatment techniques were used. We used 6 MV conventional photon CSI while Athar 
et al used 6MV IMRT; second, the field sizes were different. They based their 
simulations on simplistic 3, 6, and 9 cm diameter fields to treat hypothetical tumors in 
the head and neck and spine region, while our results were from clinically realistic CSI 
treatments which extended from the superior aspect of the brain through S2 of the 
sacrum, with more scatter dose and leakage dose from CSI. 
It is also interesting to compare our predicted risk calculations with the CCSS 
published second cancer incidence data. The cumulative risk of incidence of second 
malignant neoplasms in childhood cancer survivors was around 2% and 9% at 15 years 
and 30 years time since diagnosis. The cumulative risk for photon CSI in our study 
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were 0.5% and 4.4% at 15 years and 30 years time since diagnosis, respectively; and 
0.05% and 0.5% for proton CSI at 15 years and 30 years time since diagnosis (Figure 
4-1). A possible explanation why the published incidence are higher than ours is the 
published rates were based on the whole CCSS patient cohort and second cancers from 
all causes, including patients with various primary childhood cancer diagnosis and 
patients who received chemotherapy, while our calculated result was based on 
radiogenic second cancer risks for one patient. 
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Figure 4-1 Cumulative second cancer incidence from CCSS study (Meadows et al 
2009, Reprinted with permission. © 2008 American Society of Clinical Oncology) and 
from this study. 
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 Mu et al (2005a) compared different treatment plans, including a conventional 
photon plan, intensity modulated photon therapy plan, conventional electron plan, 
intensity modulated electron therapy plan and intensity modulated proton therapy plan 
for childhood medulloblastoma cases (5 patients). Because they did not include stray 
radiation dose in their study, the therapeutic absorbed dose to the heart was compared 
here (Table 4-4). The dosimetric results agree very well between theirs and our work. 
 
Table 4-4 Mean therapeutic absorbed dose to the heart (averaged for different cases, 5 
cases in Mu et al (2005), and 18 in current work) from photon and proton CSI. 
 
Mean therapeutic absorbed dose to the heart  
Photon Gy (s.d.) Proton Gy(RBE) (s.d.) 
Mu et al (2005) 11.9 (0.9) 0.0 (0.0) 
This work 10.4 (2.2) 0.2 (0.2) 
 
NTCP calculation results from this study are generally consistent with previous 
reports of NTCP comparisons between photon and proton therapies. Mu et al (2005a) 
reported very low NTCP values for late effects using historical NTCP model parameters 
(Burman et al 1991) to calculate side effects for five children diagnosed with 
medulloblastoma, and their explanations for the very low NTCP values included: “low 
total dose; the predictive ability of the NTCP models has not been fully tested for late 
side effects; the dose distribution and clinical data on which the models are based 
reflect irradiation conditions in the specific patient group, and there are no available 
NTCP parameters based on data sets derived from a pediatric population; and the 
relevant end-points in a pediatric population might not always be the same as in an 
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adult population”. We concur with these points, which are also applicable to our study, 
and they will be discussed later (section 4.7). 
 
4.5 Implications and significance of the findings 
Risks of radiogenic late effects associated with modern radiation therapies for 
pediatric patients are of particular interest because a relatively longer survival time after 
their treatment and higher degree of radiation sensitivity compared to adults. 
This work has several implications for CSI of pediatric patients with modern 
radiation modalities.  In order to develop strategies to minimize radiation 
complications, one first needs accurate, complete, and personalized radiation dose 
reconstructions. However, just as dose reconstructions and risk estimations have 
become more realistic, they are becoming increasingly complex, and a 
multidisciplinary effort will be advantageous to achieve breakthroughs (Newhauser 
2010, Newhauser and Durante 2011). This work suggests the feasibility of utilizing 
infrastructure and knowledge from medical physics, biology, radiation epidemiology, 
and statistics toward achieving the goal of improving patients’ quality of life. 
An important finding of this work was that proton CSI confers a lower predicted 
risk of radiogenic second cancer compared to photon CSI for one pediatric patient for 
follow-up times up to 95 years. The uncertainty analysis demonstrated the RRR values 
were sensitive to mean radiation weighting factor Rw  for neutrons and dose-risk 
models. However, the qualitative finding of this study was unchanged, regardless of the 
changes of Rw  values in a plausible range and changes of possible dose-risk models 
considering cell sterilization effects.  
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Furthermore, this work revealed that proton CSI confers a lower predicted risk 
of radiogenic cardiac toxicity for the whole heart, pericardium and myocardium 
compared to photon CSI for a population of pediatric patients.  The uncertainty analysis 
demonstrated that the RNTCP values were sensitive to the mean radiation weighting 
factor Rw  for neutrons and NTCP model parameters. However, the qualitataive finding 
was unchanged regardless of the changes of Rw  values and NTCP model parameters 
over their respective plausible intervals.  
 
4.6 Strengths of this study 
Our study has several strengths. First, we used realistic patient data from 
clinically deployed treatment planning system and the risk calculations were based on  
dose distributions from clinically realistic CSI treatment fields. Our in-house Monte 
Carlo simulation code system allowed us to generate patient-specific voxelized 
phantoms and accurate stray radiation doses from proton CSI were reconstructed. 
Previously, the stray doses and associated risks in proton therapy were assessed either 
in comparatively simplistic stylized computational phantoms or using simplistic 
circular therapeutic fields (Zacharatou Jarlskog and Paganetti 2008, Athar and Paganetti 
2009, Fontenot et al 2009, Newhauser et al 2009). Although there were several 
treatment plan comparison papers published before comparing different CSI modalities, 
the stray radiation were not included in most of them. For the proton part, Monte Carlo 
simulations were used to obtain stray radiation dose; and for the photon part, the 
detailed TLD measurements were carried out to obtain stray radiation dose specifically 
for CSI patients. These advanced dose reconstruction tools provided us with the most 
 88 
accurate and comprehensive evaluation of radiation doses and risks of any comparative 
CSI study. 
Second, we included both therapeutic and stray radiation dose in our 
calculations. Most of the previous studies or relevance to this work only included 
therapeutic dose or only stray neutron dose in proton therapy (Miralbell et al 2002, 
Zacharatou Jarlskog and Paganetti 2008, Athar and Paganetti 2009, Taddei et al 2009, 
Taddei et al 2010c). Only one study included both therapeutic and stray radiation dose 
for CSI (Newhauser et al 2009), and the comparison between this study and ours was 
discussed in section 4.4. 
Third, we calculated both second cancer incidence and NTCP of cardiac toxicity 
based on most updated dose-risk model and model parameters, which were rarely done 
before. The risk models from BEIR VII (2006) report allowed us to estimate risk of 
second cancer incidence by taking the patient’s age at exposure, attained age, and sex 
into account. The NTCP models based on clinical data of cardiac toxicity end points 
allowed us to estimate risk of cardiac toxicity for each heart sub-structure. It was 
recommended that clinical outcomes of certain organ are better correlated with NTCP 
parameters derived from the DVH of the same organ (Gagliardi et al 2010). Thus the 
detailed contouring of the heart is a special strength of this study, which provided us 
DVH information for each heart sub-structure and allowed us to do NTCP calculations 
for each of them.  
Fourth, this study used, apparently for the first time, the stray neutron doses for 
NTCP calculations. Historically, the input dose data for NTCP model were typically 
photon dose. Recently, proton dose was incorporated into NTCP calculation, and 1.1 
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relative biologic effectiveness (RBE) was assigned for proton beams (Kaser-Hotz et al 
2002) or wR =2 was used for proton beams (Mu et al 2005a). The neutron dose was not 
included for two possible reasons: first, the neutron dose equivalent was hard to 
estimate, especially for proton CSI; second, there are complexities and large 
uncertainties associated with radiation weight factor for neutrons.  In our study, both 
proton and neutron dose equivalent were included in the total dose and NTCP 
calculations, based on TPS and Monte Carlo simulations. Although the breadth of the 
range of possible neutron Rw values is controversial, the sensitivity test in this study 
demonstrate that proton therapy confers significantly lower risk of cardiac toxicity than 
photon therapy, regardless of the uncertainties in neutron Rw  values. 
Finally, the methodology used in this study to calculate the risks of radiogenic 
second cancer and cardiac toxicity is applicable to other radiogenic late effects and 
radiation modalities. Our task was and is trying to answer the important question, “How 
can we reduce the risk of radiogenic late effects like second cancers?” We predicted the 
risk of developing second cancers and other late effects for pediatric patients’ treatment 
plans and compared the different radiation treatment modalities. Ultimately, the 
research methods and results reported here may be translated to routine clinical 
treatment planning. This will enhance clinicians evidence base, upon which clinical 
decisions are made, e.g., to utilize proton vs. photon CSI.  
 
4.7 Limitations of this study 
This study has several limitations. First, only one pediatric patient was used for 
the estimation of radiogenic second cancer risk because of time and resource 
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constraints. Future calculations based on more patients may give us more information 
and provide a more realistic comparison between different modalities.  
Second, although the current risk models may not be applicable to organs 
received high therapeutic dose, a previous study found the final RRR values were not 
sensitive to dose-risk models (Fontenot et al 2010a), and the sensitivity test to the 
thyroid of a 4-year-old boy in this work demonstrated that proton CSI would always 
confer a lower predicted risk compared to photon CSI.  
Third, dose measurements at selected positions within the phantom were used to 
estimate mean organ stray equivalent dose in photon therapy, while Monte Carlo 
simulations were used to determine stray equivalent dose in proton therapy. This could 
introduce systematic uncertainties in to the comparison of dose and risk between these 
two modalities. However, the TLD measurements were specially designed for CSI. To 
the best knowledge of the authors’, those data are the most accurate and up-to-date 
stray radiation dose reconstructions for photon CSI.  
Fourth, we were unable to compare directly to epidemiological data or apply a 
risk model that was specifically for children receiving CSI. This was principally  
because we don’t have long-term follow-up data on second cancer or cardiac toxicity 
for the pediatric patients we studied. NTCP models have been used in clinic for plan 
evaluation and optimization for decades. However, some aspects of these models and 
their applications remain controversial. The low clinical complication rates and small 
number of patients involved are the basic difficulties in data collection for determining 
model parameters to predict normal tissue complications. The general agreement is that 
the calculated NTCP values are highly dependent on the clinical data from which the 
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model parameters were derived, therefore more data are needed to test the validity of 
current models (Cox et al 1995, Kwa et al 1998, Moiseenko et al 2000, Schultheiss 
2001, Seppenwoolde et al 2003). The calculated NTCP values are more suitable for a 
comparative study instead of being absolute predictors (Fuss et al 2000, Pierce et al 
2002). Additionally, the exit dose to heart is low, especially in proton therapy, which 
may cause high uncertainty in NTCP calculations. However, the exhaustive sensitivity 
tests strengthened our conclusion and gave us enough confidence to claim that proton 
CSI will deliver lower risk of cardiac toxicity compared to photon CSI.  
Fourth, the methods for radiographic identification and delineation of the sub-
structures of the heart, e.g., pericardium and myocardium, is not standardized and the 
uncertainty in heart contouring is not fully understood. Martel et al (1998) defined the 
pericardium volume as a 1 cm thick rind within the contoured heart volume for 
pericarditis study; Gagliardi et al (Gagliardi et al 2001) defined the heart with ‘the 
cranial limit of the heart included the infundibulum of the right ventricle, the right 
atrium, and the right atrium and auricle and excluded the pulmonary trunk, the 
ascending aorta and the superior vena cava’, and defined myocardium ‘with the same 
external contour as the heart. The wall thickness of the left ventricle was assumed to be 
between 2 and 3 times that of the right ventricle’; Wei et al (2008) defined pericardium 
as 0.5 cm shell extending from the heart contours for pericardial effusion study. In our 
study, the heart contouring may be simplified, but this kind of simplification is 
warranted considering the large uncertainties associated with the NTCP model itself. 
Again, the sensitivity tests of varying the heart contouring strengthened our conclusion 
that proton CSI confers lower risks of cardiac toxicity than photon CSI. 
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Finally, we only investigated a passively scattered proton CSI and conventional 
photon CSI in this work, while the other CSI modalities like scanned proton beams and 
IMRT were not studied. Further study should be carried out for those advanced 
radiation treatment modalities. 
 
4.8 Future work 
 
Calculating risk of radiogenic second cancer for a population of pediatric 
patients is a next logical step of this research. Although the same methodology used in 
this study on one pediatric patient will be used to do the calculations for other patients, 
it is desirable to have more data of risk values of second cancer. Comparison between 
different treatment modalities based on those data will be helpful. For example, such 
data will allow us to determine if our result is statistically significant for a population of 
patients. 
As we mentioned in the limitations of this work, the dose measurements at 
certain locations were used to estimate photon stray dose in each organ, while the 
detailed Monte Carlo simulations were used to simulate stray neutron dose in proton 
therapy. Several groups are developing Monte Carlo photon simulation codes that 
include a Linac-based photon therapy model and patient specific phantom for photon 
dose simulations. Such tools will be important for future photon dose reconstructions 
and risk assessment research. 
Proton CSI was compared to conventional photon CSI in this work. In the 
future, it will be important to know if other treatment modalities like Volumetric 
Modulated Arc Therapy (VMAT) and Tomotherapy are better choices in certain 
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situations, considering multiple factors such as treatment time and cost, as well as 
predicted patients outcomes. 
In the future, It will be helpful to have an evidence-based tool with a user-
friendly graphical interface to select the best treatment modality for any specific 
pediatric patient, based on their age at exposure, sex, size, disease site, etc. The current 
clinical treatment decisions rely heavily on subjective judgment and experience. A 
more quantitatively, evidence-based radiotherapy modality selection process may help 
clinicians be more objective in making clinical decisions. In our laboratory, work is 
underway to automate evidence generation for use in treatment modality decision-
making, taking into account various radiogenic late effects and considering various 
radiation treatment modalities. This work provided prototype component of such 
system, and our findings strongly suggest that a quantitative evidence-based approach 
to avoid radiogenic late effects is not only technologically feasible, but it has a large 
potential to reduce the burden of treatment related health complications experienced by 
long-term survivors of childhood cancer.  
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5. CONCLUSION 
 
Proton CSI can significantly reduce the calculated risk of radiogenic second 
cancer following CSI compared to photon CSI. Baseline calculations of the Ratio of 
Relative Risk (RRR) were always less than 1 after 15, 30, 45, 60, 75, 95 follow-up years 
for a 4-year-old boy. The Lifetime Attributable Risk (LAR) values were 7.7% and 92% 
after proton CSI and photon CSI, and Ratio of Lifetime Attributable Risk (RLAR) was 
0.083 for this boy. Sensitivity analysis revealed that quantitative values were sensitive 
to uncertainties in the risk model and the radiation weighting factor for neutrons. 
However, the qualitative findings of the study were insensitive to any plausible changes 
of risk models and mean neutron Rw  values. 
Proton CSI can also significantly reduce the calculated risk of radiogenic 
cardiac toxicities compared to photon CSI. The mean ratio of normal tissue 
complication probability (RNTCP) values for the whole heart, pericardium and 
myocardium for the whole population of pediatric patients were 1.66×10-2, 3.46×10-4  
and 3.70×10-3, respectively. Statistical tests showed that the risks of radiogenic cardiac 
toxicity from proton CSI were statistically significantly lower than the risks from 
photon CSI. Sensitivity analysis revealed that RNTCP values were sensitive to 
uncertainties in the NTCP model parameters, the mean neutron Rw  values and heart 
structure contours. However, the qualitative findings of the study were unchanged with 
the changes of NTCP model parameters, mean neutron Rw  values and heart contouring 
in plausible ranges of parameter values. 
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